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ABSTRACT OF DISSERTATION
In Vitro and In Vivo Studies on Bone Formation
by
Charmaine Richman
Doctor of Philosophy, Graduate Program in Anatomy
Toma Linda University, March, 2000
Dr. Subburaman Mohan, Chairperson

The research focus of this dissertation deals with two major issues relevant to
osteoporosis, the most common metabolic bone disease. These two aspects are: 1) mechanisms
that are involved in the regulation of peak bone density, and 2) evaluation of the in vivo effects of
Insulin-like Growth Factor Binding Protein-5 (IGFBP-5) as a potential means to treat
osteoporosis.
The first study compared two strains of inbred mice, one with high bone density and one
with low bone density, to determine when and to what extent bone density accumulation during
postnatal and pubertal growth contributed to the observed differences in bone density between the
two strains. We found that the high density strain gained more bone faster than the low density
strain, from as early as postnatal day 7 through day 35 at the end of puberty. The future
identification of the differences in gene expression between the two strains during these periods
of skeletal growth will be helpful in identifying genes that determine peak bone density in mice.
In the second study we treated inbred mice with local or systemic doses of a novel growth
factor, IGFBP-5. It is one of six high affinity binding proteins that belong to the IGF system.
Compared to the other IGFBPs IGFBP-5 has several unique characteristics: 1) IGFBP-5 has been
shown to consistently enhance the mitogenicity of IGFs in osteoblasts; 2) it accumulates in bone,
along with its bound IGFs, due to its ability to bind some extracellular matrix proteins and
hydroxyapatite in bone; and 3) it has the potential to increase cell proliferation via its specific
receptor. Therefore, IGFBP-5 has the potential to increase bone formation via IGF-dependent
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and independent mechanisms. IGFBP-5 administration alone or in combination with IGF-I
increased several bone formation parameters in serum and in bone extracts more than an
equimolar dose of IGF-I alone. This effect was independent of changes in serum IGF-I levels.
This is the first in vivo study to show the potential bone forming action of IGFBP-5 and these
findings suggest that IGFBP-5 might be a potential anabolic therapy that increases bone
formation in vivo.

CHAPTER ONE
BACKGROUND
A. Introduction
Osteoporosis is one of the most important problems confronting public health
management worldwide today. As the population of the world ages, especially in developed
countries such as the USA, the risk of developing osteoporosis and its associated deleterious
effect on quality of life, due to fracture, is enormous. An estimated 1.5 million osteoporosis
related fractures occur yearly in the USA (1) and osteoporosis costs USA taxpayers 6-10 million
dollars in health care annually (2-5). The identification and/or characterization of potential
therapeutics or interventive measures that will decrease the risk or protect the population against
developing osteoporosis are essential in an effort to stem the tide of increasing health costs of
osteoporotic sequelae and related decreased quality of life (6, 7).
B. Osteoporosis
Osteoporosis has been characterized by a decrease in bone mass. Clinically this is
manifest as decreased areal (two dimensional measurement of bone density in mg/cm2) bone
density, and a decrease in trabecular number, thickness and continuity which leads to a weakened
bony framework with fractures occurring following minimal trauma or everyday activity (8).
Primary osteoporosis occurs in postmenopausal women (type 1 or “postmenopausal”
osteoporosis) and in aging men and women (type 2 or “senile” osteoporosis), while secondary
osteoporosis occurs when bone loss is a side effect of a distinct clinical disease or treatment
regime, for example hyperparathyroidism and glucocorticoid-induced osteoporosis following
organ transplantation (9). Previous studies have shown that osteoporotic bone has the same
mineral to collagen ratio, but it may not have the same matrix composition or mineralization
quality as bone found in healthy young human adults (10-12). The etiology of postmenopausal
and senile osteoporosis is multi-factorial (13). Some factors that play a role in the development
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of osteoporosis are age, genetics, hormones, environment and physical properties of bone. These
factors are discussed briefly below.
1. Age
Bone mass stabilizes when peak bone density is attained at the end of puberty. For
reasons not fully understood, with aging, bone and muscle mass decreases (14) while fat mass
increases (15). The etiology of this age-related decrease in bone mass is heterogeneous and is
different from site to site in the skeleton (14). The resulting bone fragility predisposes the elderly
to non-traumatic fracture and it’s accompanying morbidity (see Composition of Bone under the
section on Physical Properties of Bone).
2.

Genetics

Bone mineral density has a large genetic component. As much as 70-80% of peak bone
density is genetically determined (7, 16-19). This heritability has been traditionally attributed in
part to gender and race. Men generally have greater bone mass than do women (20, 21), although
this sexual dimorphism only becomes apparent during pubertal maturation (22). This
dimorphism is subject to some controversy. Kelly et al. have shown that, when corrected for
area, women have greater bone mineral density at the lumbar spine and are not different from
men at the femoral neck (23). Because men have larger body and bone size than do women, the
resulting areal bone density is greater, there may be no difference in the true volumetric density
of bone in the two sexes as measured in g/cm3 (24).
A similar finding is true for the association of race or ethnicity and bone mineral density.
Some studies on possible differences in bone density between different ethnic groups have shown
that African American women have a higher areal bone mineral density than do non-Hispanic
Caucasian women (25, 26). The potential for a difference in bone density between ethnic groups
might be associated with different rates of bone turnover (26, 27), vitamin D exposure (28, 29) or
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receptor polymorphism (30, 31), calcium nutrition (32, 33), metabolism (26, 34), and especially
lifestyle factors and practices (35).
3. Hormones
It is well established that estrogen plays a major role in the development of osteoporosis
is both men and women (36). This association is much more dramatic in women who lose
estrogen at menopause resulting in 8-10 years of accelerated bone loss (20). In men with
estrogen deficiency, due either to a lack of aromatization of testosterone (37) or a defective
estrogen receptor (38) there is an associated lower bone mineral density. Other hormones such as
testosterone, thyroid hormone and parathyroid hormone also play a role in bone metabolism but
are not discussed in detail in this dissertation.
4. Environment
Environmental factors that play a role in the risk of developing osteoporosis are related to
dietary deficiencies, personal habits that impact nutrition, levels of physical activity, and falling.
By far and away the most important nutritional factor that plays a role in osteoporosis
pathogenesis is dietary calcium. Studies in adolescents have shown that adequate calcium intake
during childhood and adolescence (39) is better correlated with bone mineral density than
calcium intake in adult women (40, 41). There appear to be adaptive changes that spare calcium
mobilization from the skeleton during pregnancy (42) and skeletal calcium loss in milk during
lactation is redeposited following weaning (43, 44). These studies predict that pregnancy and
lactation do not predispose women to developing osteoporosis.
Other nutrients that play a minor role in bone metabolism are excessive dietary animal
protein, sodium and potassium, vitamins K and C, magnesium, boron, fluoride, and other trace
elements. Excessive dietary animal protein has been shown to increase the amount of calcium
lost in urine and therefore stimulate mobilization of calcium stores from bone (45, 46), but diets
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high in plant proteins do not have the same effect (47). High sodium intake also has been
associated with increased urinary loss of calcium (48, 49), while potassium intake has been
shown to improve the calcium balance and support bone density maintenance (50, 51). Vitamin
K is essential for y-carboxylation of osteocalcin and other gla proteins that play a role in bone
mineralization (52, 53). Vitamin C is essential for the posttranslational modification
(hydroxylation) of collagen molecules, the fundamental protein units of bone matrix (54, 55).
Boron has been shown to increase vertebral strength in rats (56); magnesium supplementation has
been shown to decrease fracture risk (57, 58); and fluoride, well known for its effect to make
enamel more resistant to caries, has been used therapeutically to increase bone density in
osteoporotic subjects (59-61). Thus many dietary factors play a role in bone strength and
mineralization.
Physical activity and mechanical loading are positively correlated with bone mass,
especially in adolescents. Human studies on muscle strength have shown that, similar to physical
activity and mechanical loading, muscle strength is positively correlated with bone mass. These
studies, while important, are difficult to design due to the size, reporting, nutritional and genetic
differences between the groups of human study subjects (62).
Smoking is usually a long-term habit and its role in the pathogenesis of osteoporosis has
been the subject of several studies. Because tobacco use is a habit and is not specific to any one
group in society, adjustment for other variables; such as genetic heterogeneity, environment, body
weight and size is impossible. Therefore all such studies must be interpreted with caution.
Several studies have shown that there is an increase in fracture incidence in both men and women
who smoke (63-65). This might be due to increased rate of bone loss and decreased bone
formation leading to a net bone loss (66).
Alcohol abuse has been associated with increased risk of fracture/osteoporosis in several
small uncontrolled studies, most especially in men (63, 67-73). These studies showed that
fractures occurred at a younger age than age matched controls. The association of moderate
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alcohol consumption and the risk of fracture/osteoporosis is contradictory. Some studies show an
increase in fracture incidence later in life that is proportional to the alcohol consumption (74, 75),
while others show that there is no effect (76). Areal bone density is decreased in individuals with
chronic alcoholism (66, 77). Alcoholism or alcohol abuse goes hand in hand with poor nutrition,
low body weight, liver disease, malabsorption, vitamin D deficiency, hypogonadism,
hemosiderosis, parathyroid dysfunction and tobacco consumption so that any one, or all of these
factors might predispose the individual to osteoporosis (66).
The association of osteoporotic hip fracture with falling is well documented. With aging
several physiological changes occur; including loss of visual acuity, hearing and balance
impairment, and decreased sensory awareness of the lower extremities, that predispose the elderly
to fall (78). Many other factors like chronic diseases, diabetes, Parkinson's disease and
osteoarthritis, also play a role in the risk of falling in the elderly. The actual falling event,
whether the individual falls forward onto their hands leading to wrist fracture or sideways leading
to hip fracture plays a role in the type of fracture that occurs (78).
5. Physical Properties of Bone
Physical properties of bone that play an important role in the risk of developing
osteoporosis include bone mineral density or mass, bone size and geometry, the microarchitecture
of the remaining bone, and the composition of that bone.
a) Bone Mineral Density
Bone mineral density in adults is the result of peak bone mass, attained at the end of the
pubertal growth spurt, and the amount of bone lost since that time. Areal bone mineral density on
its own is a major determinant of the risk of fracture 10-20 years after menopause, even when
considered independently from aging, estrogen status, and falls (79-81). Areal bone density
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decreases in both men and women with age, but women experience this loss earlier than men (8284).
b) Bone Size and Geometry
The size of a bone plays a large role in its strength. Larger bones are stronger than
smaller bones even if the bone volume is not different between the two bones (85). Thus with
aging, even as bone is lost on the endosteal surface, small amounts of bone are deposited
appositionally under the periosteum that may help to compensate for the endosteal lose (86-88).
Because men have larger bones than women do, although they have been shown to lose just as
much bone as women do, they are at a lower risk for fracture (89, 90). In all these studies bone
loss occurs at an earlier age in women (88, 91).
c) Microarchitecture of Bone
Bone matrix is arranged in two major architectural forms: dense cortical bone and spongy
trabecular bone. Cortical bone is found in the shafts of the long bones and on the surfaces of
other bones, and trabecular bone is found at the ends of long bones and inside flat bones (92)
Cortical bone is made up of concentric lamellae arranged around a central nutrient canal, while in
trabecular bone the lamellae run parallel. New bone is added by appositional growth at the
periosteal surface of the cortex and lost at the endosteal surface throughout life (93, 94). Human
studies have shown that cortical thickness decreases with age in both men and women but cortical
porosity only increases in women (95, 96). Trabeculae are arranged as interconnecting plates of
mineralized bone matrix and are oriented in the lines of stress to act as reinforcements for the
bone. An age related decrease in trabecular connectivity has been demonstrated in women (97,
98), while in men there is a decrease in thickness of trabeculae (97-102). This thinning of the
cortex and changes in trabecular architecture insidiously adds to other changes in bone occurring
with age.
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d) Composition of Bone
Bone is made up of cells and extracellular matrix. The cells form and resorb bone
without themselves adding to its strength or weakness, the extracellular matrix components are
what give bone its material properties. The organic protein matrix organization and its
mineralization have a great deal to do with bone strength or weakness while in motion. Bone
from older women is more fragile than bone from younger women, although the volumetric bone
density may not be different (103-105). Collagen crosslinking and structure in older bone is
greatly reduced and therefore the organic component is weaker in older bones than in younger
bones (106, 107). Older bone is more highly mineralized than is younger bone (108-110) and the
mineral crystals are larger and more spherical in osteoporotic women (111, 112) making older
bone more brittle.
In this dissertation, the study presented in Chapter Three will address, to some extent the
genetic component/s contributing to the difference in volumetric bone density between two inbred
strains of mice. By using inbred mice as a model system, we were able to control for genetic
variability inherent in other animal models, including humans. Also it is imperative to control
environmental effects so that the experimental results that are different between the two strains of
mice were not due to environmental differences. The study reported in Chapter Four will address
a potential local or systemic factor, Insulin-like Growth Factor Binding Protein-5 (IGFBP-5) that
we observe increases bone formation when delivered systemically. This factor belongs to the
Insulin-like Growth Factor (IGF) system that has been shown to play a major role in local bone
regulation and is discussed below (see section on “Regulators of Bone Turnover”).
C. Development, Growth and Maintenance of the Skeleton
The skeleton develops during the fetal period and continues to grow in size through
puberty, at the end of which growth in length is arrested although growth in diameter occurs
slowly throughout life. The skeleton is in a dynamic state of turnover at all times, including adult
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life when bone formation is roughly equal to bone resorption in an effort to maintain bone mass.
However with aging, bone formation fails to keep up with resorption so that there is a net loss in
bone leading to osteopenia and potentially osteoporosis. In the overall growth that occurs from
conception to the attainment of peak bone mass at the end of puberty there are two periods of
rapid growth (1) postnatal growth - fetal through 1 year and (2) pubertal growth - roughly from
12-18 years of age. 40-50% of peak bone mass is accrued during pubertal bone growth (113).
Since bone mass at any point in time is the sum of peak bone mass and any bone lost since the
attainment of peak bone mass, and bone mass is a strong determinant of potential risk of fracture
(79-81), manipulation of bone mass accumulation during rapid bone growth could be beneficial in
preventing osteoporosis. The processes by which new bone is formed at different skeletal sites
are described below.
1. Mechanisms of Bone Formation
Bone, like other organ systems, is derived from condensations of progenitor cells which
differentiate into chondroblasts which produce a cartilage model (anlage) that will be replaced
with bone (endochondral bone formation) or into osteoblasts and form bone de novo
(intramembranous bone formation). These two distinct mechanisms of bone formation are
discussed below.
a) Endochondral Bone Formation
During endochondral ossification, a cartilage anlage is replaced by bone and marrow as
the bone continues to grow in size. To facilitate this growth, an epiphyseal growth plate of
polarized hyaline cartilage develops at both proximal and distal ends of each long bone (114).
This growth plate consists of five zones: (1) Resting Zone is on the epiphyseal side of the growth
plate is the resting zone made up of quiescent hyaline cartilage chondrocytes. (2) Proliferative
Zone lies next to the proliferative zone; here chondrocytes are actively dividing to form isogenous
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groups that are arranged in longitudinal rows that are parallel to the long axis of the bone. These
proliferating chondrocytes create caves (lacunae) for themselves by surrounding themselves with
extracellular matrix. This proliferative zone is responsible for increasing the length and diameter
of the growing bone. (3) Hypertrophic Cartilage Zone is made up of enlarged, hypertrophic
chondrocytes that are separated from each other by the matrix they produced in the proliferative
zone. Glycogen accumulates in their cytoplasm, giving these cells a clear cytoplasm in paraffin
sections. These large chondrocytes compress the extracellular matrix into thin septae. (4)
Calcified Cartilage Zone is formed, as the hypertrophic chondrocytes become apoptotic; the
cartilage matrix becomes calcified with hydroxyapatite forming the calcified cartilage zone. (5)
Ossification Zone is characterized by macrophage type, multi-cellular chondroclasts that resorb
the inter-lacunar matrix opening up channels which allow osteoprogenitor cells derived from the
endochondral bone and marrow of the diaphysis to colonize the surface of the calcified cartilage
septae. These osteoprogenitor cells differentiate into osteoblasts and start to lay down bone
matrix (114). The primary spongiosa formed in this way is therefore composed of trabeculae
with a core of calcified cartilage matrix surrounded by layers of bone matrix. Growth in length
and width is due to chondrocyte proliferation in the zone of proliferation adjacent to the
epiphysis, with concomitant hypertrophy and degeneration of the chondrocytes on the diaphyseal
side; these two opposing events occur at an approximately equal rate, so that the epiphyseal plate
maintains a stable width (114). When growth in length is arrested at the end of puberty, the
cartilage of the growth plate is completely replaced with bone so that the epiphysis becomes
continuous with the metaphysis. Long bones are formed by endochondral ossification.
Endochondral bone formation plays a large role in fracture healing. A callus of cartilage
forms adjacent to the bony break in the cortex and with time is converted into bone by
endochondral ossification. This bony callus is modeled to restore the shape of the bone when
healing is complete (115).
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b) Intramembranous Bone Formation
In intramembranous bone formation, bone is formed de novo. The process begins with an
area of mesenchymal condensation. These mesenchymal cells differentiate into osteoblasts that
produce osteoid. This osteoid will become mineralized, encapsulating the osteoblasts and
converting them to osteocytes forming an ossification center. These islands of developing bone
form interconnecting sheets with cavities in between the sheets much like a sponge. The cavities
contain blood vessels, bone marrow cells and undifferentiated stem cells. The surrounding
mesenchyme forms the periosteum on the external surface and the endosteum on the internal
surfaces. Several such ossification centers form and grow radially, fusing to form the bones.
There is a predominance of bone formation over bone resorption, thus allowing the bone to grow.
The flat bones of the skull are formed in this way (114, 116, 117) as well as the initial bony collar
around the cartilage anlage of long bones in the embryo.
Intramembranous ossification also plays an early role in the initial bridging of the
discontinuous cortex in fracture repair. This bridge helps to stabilize the bone while cartilaginous
callus formation occurs (115).
2. Bone Growth and Maintenance from Conception through Old Age
The process of building a skeleton requires bone formation to precede bone resorption in
a process called modeling. Bone formation must also exceed resorption such that the bones
increase in size in proportion to growth of the surrounding organs. This state of growth is very
different from the bone turnover occurring from skeletal maturity until death, where bone
resorption precedes formation and is coupled to it so that the amount of bone resorbed is replaced
with a similar amount via bone formation. The different phases of bone growth and maintenance
are discussed below.
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a) Embryonic Bone Growth
Osteoprogenitor cells are derived from three distinct cell lineages in the embryo: neural
crest cells via the branchial arches will form the craniofacial skeleton, sclerotome divisions of the
somites will give rise to most of the axial skeleton, and mesenchymal cells from the lateral plate
mesoderm will give rise to limb bones (116). All the long bones are formed by endochondral
ossification while most of the craniofacial skeleton is derived by intramembranous ossification.
Both mechanisms yield immature bone, which is temporary, and eventually will be replaced by
mature bone. Immature bone is less well mineralized and it is more cellular than mature bone
because in immature bone, the collagen fibers are aligned randomly. During bone growth areas
of immature bone, areas of resorption and areas of mature bone appear side-by-side (114).
Modeling includes the appositional growth at the outer periosteal surface of the bone allowing it
to increase in diameter, chondrocytic growth in the growth plate to make the bone longer and
wider, and endosteal resorption and remodeling of the cortical plate and trabeculae to enlarge the
marrow space (117).
The hormonal environment of the fetus nurtures bone formation allowing the fetal bones
to grow in size along with the rest of the body. During fetal development the fetus produces high
levels of parathyroid hormone related peptide (PTHrP) (118) and calcitonin (119-121), while
levels of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (l,25(OH2)D3) are low due to
high serum calcium levels derived from the maternal circulation. In the fetus, IGF-I is produced
by the fetal liver in response to placental lactogen (122). Fetal IGF-I levels correlate with birth
weight and IGF-I has been shown to stimulate bone formation (123-125). Fetal serum estrogen
levels are relatively high and are derived from the mother’s blood; estrogen also acts to stimulate
bone formation (126-128).
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b) Postnatal Bone Growth
In the first few weeks of postnatal life with placental lactogen gone serum IGF-I doubles
in response to the high circulating levels of GH. Assuming adequate dietary calcium intake and
exposure to sunlight, bone mineral content increases rapidly from birth to beyond 1 year of age
with a slowing at the 6-month mark (129). Normal children have increased secretion of
leutinizing hormone (LH) and follicle stimulating hormone (FSH) for the first few months to
years after birth in response to the loss of circulating estrogen from the mother. This secretion
decreases and the juvenile pause ensues where overall growth is linear and relatively slow. There
is an increase in gonadotropin secretion in response to gonadotropin releasing hormone (GnRH)
at the start of puberty (130). In preparation for puberty, from mid-childhood there is an increase
in the pulse rate and amplitude of growth hormone (GH) secretion from the pituitary (131, 132).
In normal children serum PTH and l,25-(OH)2 D are similar to adult levels (133-136),
indicating that bone resorption is occurring at a similar rate in children and adults. GH and IGF-I
are increased during childhood and are associated with the growth in whole body size, including
bone growth and mineral acquisition (137-140). Any changes in GH or IGF-I level (deficiencies
or diseases) will affect the growth of the child.
There is little sexual dimorphism in the pattern of growth during childhood (141) and
bone mass increases in a linear manner during this time (142, 143). Several studies have shown
that the volumetric bone density is independent of age, such that a child with volumetric bone
density in the twentieth percentile at age five will still be in the twentieth percentile at age thirtyfive (144-146). Therefore volumetric bone density is determined early and is a function of bone
size and mass, which must change proportionally to allow volumetric bone density to be
independent of age (24).
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c) Pubertal Bone Growth
Puberty is a transitional stage where children develop into adults in size and reproductive
capacity. The development of secondary sex characteristics, as described by Tanner et al. (147),
is an indication of the overall changes occurring in most organ systems with puberty. During
puberty there is a rapid increase in growth and changes in body composition and proportions
(148). The progress through puberty is quite variable within each sex, such that some children
will take longer, or start earlier than others (148). Puberty starts earlier in girls and is shorter than
in boys, and these differences contribute to the sexual dimorphism in mature height (148). This
height difference is already apparent well before puberty: half-adult height is achieved by age 1.4
in girls and only at 2.2 in boys (148).
The earliest event in the pubertal hormonal cascade is still undescribed. The earliest
event observed at the start of puberty is an increase in the amplitude of GnRH release from the
hypothalamus, which stimulates the release of first, LH and then FSH. These gonadotropins act
on the gonads to release sex steroids (149, 150). Both testosterone and estrogen have negative
feedback on GnRH release (151). Concomitant with increased circulating sex hormones there is
an increase in the amplitude of GH pulsatile secretion, which in turn increases serum IGF-I (150).
This response to sex steroids is restricted to the pubertal years, as sex steroids remain relatively
elevated in adults, but GH and IGF-I levels decrease (150). The increase in GH occurs during
early puberty in girls but later in boys, correlating with the early and late growth spurts seen in
the two sexes respectively (152). The increase in GH appears to be in response to estrogen levels,
even in boys (153) where aromatization of testosterone appears to be responsible (154). A sexual
dimorphism in the quality and pattern of GH secretion has been seen in humans and rats, such
that girls produce more GH in a 24-hour period than do boys (155-157).
Circulating levels of bioactive estrogen are higher in prepubertal girls than boys (158)
and this may account for the earlier onset of puberty in girls than in boys (132, 158). The
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increase in both GH and IGF-I levels is unique to puberty (150). Before and after puberty serum
IGF-I and GH levels have a reciprocal relationship (159-161). In boys the increased levels of
androgens have been shown to increase both protein turnover and synthesis (162), and along with
GH and IGF-I to increase during puberty which also increased whole body protein synthesis (163,
164). These three hormones all increase body protein in boys during puberty. Estrogen does not
affect protein metabolism in girls (165). This difference in the effect of testosterone and estrogen
on protein metabolism may contribute to the sexual dimorphism in size and bulk developed
during puberty (150). During puberty there is a decreased sensitivity to insulin, such that insulin
levels rise (166-168). Since insulin actions directly affect carbohydrate and protein metabolism,
this rise in insulin may contribute, along with the sex steroids, GH and IGF-I, to the changes in
body composition occurring during puberty (166, 167). Testosterone and estrogen have been
shown to increase calcium absorption and retention in boys and girls, respectively (162, 169) but
these two hormones had opposite effects on calcium accretion in bone.
The growth of just about every bone increases at puberty, but the timing of this growth
varies from site to site. Growth usually begins distally in the limbs and progresses proximally to
the axial skeleton. Growth arrest follows the same pattern. Estrogen is responsible for the fusion
of the epiphyseal plates and the end of growth in both boys and girls (38). The two most
important sexual differences in the skeletal growth are the greater biacromial (shoulder) diameter
in boys and the greater increase in biiliac diameter in girls (148). De Schepper et al. have shown
that bone mass increases exponentially during puberty (142, 170). Due to the differences in
timing of the growth spurt between boys and girls, bone mass accumulation is later in boys than
in girls (171, 172). GH is essential for the acquisition of bone mass during puberty; this is
illustrated by the relative osteopenia seen in untreated GH deficient children even when the
smaller bone size is taken into account (173). GH replacement has been shown to increase bone
mass in GH deficient children (173).
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The study reported in Chapter Three illustrates that the changes in overall body weight
and skeletal growth that occur during postnatal and pubertal growth spurts are similar in mice
compared to humans, although the time frame is much shorter in mice.
d) Adult Bone Maintenance
Following growth arrest at the end of puberty, bone turnover reflects the dynamic
exchange of new bone matrix for old matrix thus keeping the skeleton supple and preventing
accumulation of glycation and matrix degradation. Bone turnover involves bone remodeling and
can be divided into 2 zones: 1) the cutting cone where osteoclasts resorb existing bone creating a
tunnel, and 2) the forming cone where blood vessels following the osteoclasts bring
osteoprogenitor cells into the tunnel. Osteoblasts will differentiate from these progenitor cells
and lay down new bone. The outer limit of the tunnel made by the cutting cone will form the
cement/reversal line that is characterized by mineralized matrix with only a few collagen fibers
(114). Remodeling occurs in discreet locations and each remodeling site is called a basic
multicellular unit (BMU) (174). Bone remodeling occurs in response to distinct signals or stimuli
such that BMUs form, carry out their function and disband leaving new bone in their wake.
Because trabecular bone has a much larger surface to volume ratio than does cortical bone, it has
a much higher turnover rate. Twenty percent of trabecular bone is being remodeled at any one
time, so that the same surface will be remodeled every 2-4 years (175). The factors/stimuli that
induce remodeling have not been fully elucidated but evidence exists that microcracks and/or
stress perceived by osteocytes in cortical and trabecular bone are responsible for increased
remodeling in an area of bone experiencing excessive stress (175).
3. Animal Models of Bone Growth and Development
Humans and other mammals all exhibit similar skeletal growth and development patterns.
However, smaller animals, especially rodents, progress rapidly through the various growth
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periods to reach sexual maturity at 4-6 weeks of age in mice and 8-10 weeks in rats. Similar to
childhood and adolescent growth phases in humans, mice exhibit rapid postnatal growth followed
by a pubertal growth spurt that slows down dramatically when sexual maturation is attained.
Unlike humans, where closure of the growth plates occurs as sexual maturation is attained, mice
continue to grow slowly in size after puberty (day 31-35) until their growth plates are thought to
close at 3-4 months of age (176). The relatively rapid progression of mice through postnatal
growth and puberty, and the easy availability of genetically identical inbred mouse strains
recommend them as an excellent model system for studying factors regulating/affecting postnatal,
pubertal and postmenopausal bone growth/loss. Pubertal growth has been shown to be very
important in the determination of an individual’s peak bone density (see section on Pubertal Bone
Growth) and therefore impacts the long-term risk for developing osteoporosis. Understanding the
relative contribution of different periods of bone growth and density accretion will help to
identify potential preventive/interventive therapies to enhance the attainment of peak bone
density and therefore decrease the risk of developing osteoporosis later in life.
D. Bone Structure
Bone is a dynamic and metabolically active tissue that is remodeled throughout life.
Each bone is lined on the outside surface by periosteum and on the inside surface by endosteum.
There are 2 main types of bone: 1) mature bone where the collagen disposition is well organized
into lamellae which form either cortical/compact bone usually on the external surface of the bone
or cancellous/trabecular/spongy bone made of numerous, interconnecting sheets of bone. And 2)
immature bone that has fine, randomly oriented collagen fibers in the matrix. Both types of bone
have the same basic histological structure (177).
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1. Architecture of Mature Bone
The periosteum covers the external surfaces of the bone and is a fibrous layer composed
of collagen and fibroblasts with an inner more cellular layer of osteoprogenitor cells adjacent to
the outer bone surface. Some periosteal collagen fibers penetrate the bone matrix as Sharpey's
fibers and these fibers bind the periosteum to bone. The endosteum lines all the internal surfaces
of bone and is much thinner than the periosteum. It comprises a single layer of osteoprogenitor
cells and very little connective tissue. The function of these two membranes is to supply new
osteoblasts when needed and to nourish the existing bone and osteoclasts are found within these
membranes when they are actively resorbing bone.
Bone is made up of an osteonal system, where each osteon has a central canal parallel to
the long axis of the bone and concentrically arranged lamellae of mineralized extracellular matrix
surrounding the canal. Interconnecting the central canals of adjacent osteons to the periosteum
and marrow cavity are Volkmann’s canals that perforate the lamellae perpendicular to the central
canal. These canals carry blood vessels, nerves and lymphatics embedded in a loose connective
tissue. The collagen fibers in each lamella are laid down in parallel, and follow a helical course
that is perpendicular to collagen of adjacent lamellae. There are 4-20 concentric lamellae per
osteon with osteocytes in their lacunae lying between each lamella (114). Cementing substance,
which has only a few collagen fibers in the matrix, delineates each osteon. Interstitial lamellae
are lamellae of previous osteons that have been disrupted due to continuous remodeling of the
bone tissue. Circumferential lamellae are laid down by appositional growth on the inner and
outer periosteal surfaces of the bone; there are fewer circumferential lamellae on the endosteal
surface than on the periosteal side (114).
Bone Marrow fills the hollow shafts and spaces of bones. There are two types of bone
marrow: 1) red marrow is made up of hematopoietic stem cells (blood cell precursors), stromal
cells (osteoblast and adipocytes precursors, and mesenchymal stem cells) and a few adipose cells;
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it is generally found in only specific sites in the adult e.g. sternum, ribs, iliac crest and vertebral
bodies; and 2) yellow marrow which is mostly adipose tissue is found in the shafts of long bones,
and may revert to red marrow when necessary.
2. Bone Cells
Osteoprogenitor cells, derived from mesenchymal stem cells, are spindle shaped cells in
the cellular layer of the periosteum and endosteum. They exhibit little rough endoplasmic
reticulum and a poorly developed Golgi complex. They can be recruited to form osteoblasts that
produce new bone, making them very important in bone growth and repair (178).
Osteoblasts line bony surfaces and can be active or quiescent; when active they produce
the organic component of the extracellular matrix, called osteoid, which is laid down over
existing bone. Osteoblasts are essential for mineralization of osteoid. They are typical protein
producing cells i.e., polarized cuboidal to columnar cells lining the surface of the bone. The
nucleus is at the base of the cell, opposite to the bone surface. The cytoplasm is basophilic due to
the extensive endoplasmic reticulum, and there is a well developed Golgi complex. When
osteoblasts are quiescent they are flattened with less basophilia of the cytoplasm. Osteoblasts
remain in contact with adjacent osteoblasts by cytoplasmic processes and communicate via gap
junctions (179).
Osteocytes are formed when osteoblasts become entrapped in the osteoid they produce
(180, 181). They come to lie in lacunae between the lamellae of matrix as it is laid down. There
is only one osteocyte per lacuna. Osteocytic cytoplasmic processes run thorough canaliculi
within the bone extracellular matrix to make contact with other osteocytes or osteoblasts via gap
junctions (181). Osteocytes are thought to actively maintain the bone matrix by local responding
to mechanical and chemical stimuli (182). Some molecular exchange occurs between blood
vessels, extracellular fluid and osteocytes; this mode of exchange can support a chain of up to 15
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osteocytes (114). Osteocytes have less rough endoplasmic reticulum, a small Golgi and more
condensed chromatin than do osteoblasts.
Osteoclasts are very large, multinucleated, extensively branched and irregular, motile
cells. They are derived from fusion of osteoclast precursor cells derived from hematopoietic stem
cells (183-185) and contain 5-50 nuclei in the large body of the cell. Actively resorbing
osteoclasts lie within enzymatically etched depressions on the bone surface called resorption
(Howship’s) lacunae. They have acidophilic cytoplasm with lots of mitochondria and lysosomes,
and a well developed Golgi complex. Active osteoclasts have a ruffled border that has folded
irregular projections of cytoplasm facing the bone surface. A clear or sealing zone surrounds the
ruffled border and is devoid of organelles but rich in actin, this area adheres to the bone matrix
creating a microenvironment for bone resorption (186, 187). Into this resorption zone, the
osteoclast secretes acid, collagenase and other proteolytic enzymes, which digest the collagen and
noncollagenous proteins, and liberate the hydroxyapatite; these are taken up in cytoplasmic
vacuoles and broken down in lysosomes (188).
3. Extracellular Matrix
The organic component of bone extracellular matrix is made up of two main groups of
proteins: collagenous and noncollagenous. Type 1 collagen makes up 95% of the total protein
content of bone matrix and as such makes up the major framework of bone (189). Within this
framework noncollagenous proteins are bound or adsorbed and the inorganic mineral is
deposited. Noncollagenous proteins make up the remaining 10-15% of the organic component
(189). A quarter of these noncollgenous proteins are acidic proteins which bind to the inorganic
hydroxyapatite mineral and are derived exogenously, such as albumin from serum, growth factors
from serum and the local extracellular milieu, and traces of other molecules (190). Osteoblasts
produce an equal number on a molar basis of endogenous noncollagenous protein molecules as
they do type 1 collagen, even though noncollagenous proteins are, in general, much smaller in
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size than collagen (189). The functional role of many noncollagenous proteins is not fully
elucidated. Bone noncollagenous proteins can be divided into 4 general groups: proteoglycans,
glycosylated proteins, cell-attachment proteins and y-carboxylated proteins. The organic
component of the bone extracellular matrix makes up 35% of dry bone weight and is responsible
for bone strength in tension (189).
The inorganic components of bone extracellular matrix are calcium and phosphorus that
occur mostly as crystalline hydroxyapatite, but some amorphous calcium phosphate is also
present. The inorganic component of the bone extracellular matrix makes up 65% of dry bone
weight and is responsible for bone strength in compression (189). This inorganic component is
responsible for the “density” that is measured in vivo.
E. Regulators of Bone Turnover
Bone formation and resorption are coupled, such that following resorption by osteoclasts
bone formation by osteoblasts is stimulated to replace the resorbed bone (191-194). This
coupling is brought about by systemic and local hormones/factors.
1. Systemic Regulators
Hormones that regulate bone turnover are mostly involved in calcium homeostasis, i.e.
parathyroid hormone (PTH), calcitonin and 1,25 (OH)2 D. Calcium levels are kept within a very
narrow range in blood so that when blood calcium falls, PTH is rapidly released. PTH increases
1,25 (OH)2 D production. These two hormones increase serum calcium. When serum calcium
rises calcitonin is released to reduce serum calcium levels.

a) PTH
PTH is secreted by the parathyroid chief cells and its serum levels are largely regulated
by serum calcium. Acute increases in serum PTH in response to decreased serum calcium: 1)
stimulate the distal tubule of the nephron in the kidney to reabsorb more calcium, but decrease
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reabsorption of phosphorus in both proximal and distal tubules; 2) activate osteoclasts to resorb
bone to release calcium into the blood; and 3) increase the activity of vitamin D 1-a-hydrolyase
in the kidney proximal tubule to convert more 24 cholecalciferol to 1,25 (OH)2 D. 1,25 (OH)2 D,
the active metabolite of vitamin D, increases the absorption of calcium and phosphorus from the
intestine (195, 196) and stimulates osteoclast formation and bone resorption.
b) Vitamin D
Vitamin D is made in the skin by exposure to sunlight and then hydroxylated first in the
liver and then in the kidney to its active metabolite, 1,25 (OH)2 D. The limiting steps in vitamin D
activation are exposure to sunlight and the production of vitamin D 1-a-hydrolyase in the
proximal tubule of the kidney which is under the control of serum PTH. 1,25 (OH)2 D increases
serum calcium by increasing calcium absorption in the proximal small intestine and recruiting
osteoclast precursors to become osteoclasts which resorb bone and release calcium into serum
(197).
c) Calcitonin
Calcitonin is secreted by the C-cells of the thyroid gland and its main action is to inhibit
osteoclastic bone resorption. Calcitonin is secreted when there is a rise in circulating calcium.
Active osteoclasts rapidly respond to increased serum calcitonin. They shrink in size, detach
from the bone surface and stop resorbing bone (198). This acute response is mediated by the
calcitonin receptors that are highly expressed on osteoclast membranes (199).
d) Sex Steroids
Sex steroids are produced by the sex organs of the respective genders, ovaries in females
and testes in males. The production of sex steroids is under control of the hypothalamus via the
pituitary. Estrogen deficiency plays an unequivocal role in the development of osteoporosis in
postmenopausal women and aging men (200). Estrogens, aside from their role in reproduction,

21

play an important role in bone development, growth, and loss, as well as inhibiting osteoclast
formation and activity. The role of progesterone in osteoporosis has been less well characterized
but appears to be similar to that of estrogen (201). Testosterone has been shown to act on
osteoblasts by being converted into either 1) estrogen by an aromatase exerts its effects via the
estrogen receptor; or into 2) dihydroxytestosterone by 5oc-reductase and works through the
androgen receptor (202).
2. Local Regulators
Local regulators of bone formation and resorption act in an autocrine/paracrine manner
and therefore are produced by cells in the local bone environment such as osteoblasts, osteoclasts,
and cells of the bone marrow.
a) IGF system
The insulin-like growth factor (IGF) system has been shown to modulate growth in many
tissues, such as nervous tissue (203), lymphoid tissue (204), reproductive tissue (205), smooth
muscle (206, 207), endothelium (208, 209) and bone (123, 210, 211). A number of in vitro and in
vivo findings demonstrate that IGF-I and IGF-II are important regulators of bone formation.
When added exogenously, both increase osteoblast cell proliferation and differentiation in vitro
(212, 213) and bone formation in vitro and in vivo (124, 137). Serum and bone IGF-I levels have
been shown to decrease with age, which may contribute to the decreased bone formation also
associated with aging (214, 215). Mice lacking functional IGF-I and/or IGF-II genes exhibit
severe impairment of bone formation (216-218). In addition, an adolescent male human with a
disrupted IGF-I gene had a bone mineral density significantly less (5 SD below normal BMD)
than that found in other studies of healthy adolescent human males (219). The IGF system is
made up of two IGF ligands, two IGF receptors, six high affinity IGFBPs and specific and
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nonspecific proteases that degrade IGFBPs, as well as, at least four IGFBP-related proteins that
bind IGFs with low affinity (220).
(1) IGF Ligands
IGF-I and IGF-II are anabolic peptides, closely related to insulin by structure and
function (221). IGFs are produced by many tissues throughout the body including osteoblasts
they act as autocrine/paracrine as well as endocrine growth factors (222). IGF-I and IGF-II
mediate their mitogenic and anabolic effects by binding to plasma membrane receptors. Like
other growth factors, IGFs activate a sequential protein-kinase pathway by binding to their
membrane receptors (223, 224). This ultimately results in convergence in the nucleus and
regulation of activation of transcription factors, thus regulating growth. Serum IGF-I is derived
mostly from the liver and it mediates most of the GH effects in many tissues (216, 225). In other
tissues IGF-I production is controlled mostly by factors other than GH. Targeted disruption of
IGF-I/II in mice has shown that IGFs are essential for normal development (216, 217, 225).
IGFBPs exist in excess of IGFs; so there is very little free IGF available to tissues from serum.
The mechanisms responsible for IGF liberation and delivery to the local tissue has been the
subject of several studies (226-228). IGF-I and IGF-II are the most abundant growth factors
produced by osteoblasts and are released into the extracellular fluid, where some bind IGF
receptors on neighboring cells, some find their way into the general circulation and some bind
IGFBP-5 and are stored bound to bone matrix (229).
The IGF-I gene is complex comprised of 6 exons with alternate promoters in exon 1 and
2 (230-232). The IGF-I exon 1 promoter is responsible for regulation of extrahepatic expression
including bone and it has response elements for several hormones (232). The IGF-I exon 2 is
primarily responsible for IGF-I expression in response to GH and is therefore most active in liver
(233).
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Both local and systemic factors regulate IGF-I gene expression in osteoblasts. PTH,
PTHrP and prostaglandin E2 (PGE2) through cyclic AMP induction stimulate IGF-I synthesis.
Therefore some of the anabolic effects of PTH are mediated via IGF-I (233-239).
Glucocorticoids decrease IGF-I expression in rat osteoblasts (240), but had no effect on IGF-I
expression in human osteoblasts (241). Platelet Derived Growth Factor (PDGF), Transforming
Growth Factor-P (TGFP), and Fibroblast Growth Factor-2 (FGF-2) decreased IGF-I expression in
rat osteoblasts (242)but TGFp increased IGF-I expression in mouse calvarial organ cultures.
Interleukin-1 (IL-1) and PGE? also increased IGF-I expression in mouse calvarial organ culture
(238).
(2) IGF Receptors
There are two plasma membrane receptors in the IGF system. The type 1 IGF receptor
binds IGF-I and -II with equal affinity and appears to be the predominate receptor involved in
mediating the effects of IGF-I and -II in most cell types, including osteoblasts (243, 244). The
type 2 IGF receptor binds only IGF-II and has a 99% homology with the mannose-6-phosphate
receptor (245). The mannose-6-phosphate receptor is involved in delivering lysosomal enzymes
targeted to endosomes by mannose-6-phosphate glycosylation in the Golgi (246). While the type
2 IGF receptor most likely plays a role in recycling IGF-II(247, 248). No conclusive down
stream signaling mechanism associated with this receptor has been established. When IGF-I/II
bind to the extracellular domain of the IGF type 1 receptor, the associated intercellular tyrosine
kinase is activated to phosphorylate insulin receptor substrate 1, insulin receptor substrate 2 and
She which then associate with phosphatidylinositol 3' kinase and its signaling cascade (249); 1)
activation of the Ras-mitogen-activated-protein kinase signaling pathway (250); 2) down
regulates Src activity by interacting with C-terminal Src kinase; and 3) activates the Janus
(JAK)/signal transducers and activators of transcription (STAT) pathway (251) to regulate cell
growth and metabolism.
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(3) Insulin-like Growth Factor Binding Proteins
There are six high affinity binding proteins in the IGF system. These IGFBPs modulate
the actions of secreted IGFs by binding to them and increasing the IGF’s half-life in the
extracellular milieu and circulation by sequestering them in this bound form. The IGFBPs either
enhance or inhibit IGF actions on target cells (252, 253). In bone the individual IGFBPs either
inhibit or potentiate IGF effects on osteoblasts (252-258). In vitro studies have shown that
IGFBP- 1, 2, 4 and 6 inhibit IGF effects (252, 253), while IGFBP-3 has been shown to be either
inhibit or potentiate in turn (259, 260), and IGFBP-5 consistently potentiates them (257, 261263), except when present in large excess of IGFs (264). The IGFBPs exist in the circulation in
two forms, 1) the 50-kDa form where IGFBP is bound to either IGF-I/II or 2) the 150-kDa form
where IGFBP-3/-5 is bound to IGF-I/II and an acid labile subunit. The 50-kDa form can easily
pass through the vascular wall while the 150-kDa form is trapped in the circulation. This 150kDa complex increases the pool size of circulating IGFs and may act to potentiate their action in
this way. These pools are in equilibrium with each other so that the IGFs are freely exchanged
between 50- and 150-kDa forms (253).
Of the IGFBPs, IGFBP-5 is unique in that it: 1) consistently potentiates IGF induced cell
proliferation (257, 261-263); 2) binds to the extracellular matrix proteins and hydroxyapatite of
mineralized bone with high affinity and is therefore stored in bone with its bound IGF (215, 265,
266); 3) IGFBP-5 binds to the acid labile subunit in serum therefore increasing the half-life of
IGFs in the serum (267); and 4) IGFBP-5 has been shown to act independent of IGFs and induce
cell proliferation via its own receptor (257, 268). IGFBP-5 along with IGF-I/II stored in bone has
been shown to decrease with age reflecting the possibility that its production changes with age
and might contribute to the decrease in bone formation that occurs with age (214, 269). The
IGFBP-5 with its associated IGFs stored in bone is thought to play a role in the coupling of bone
formation to resorption, such that during bone resorption these stored factors are liberated to act
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in a paracrine manner and initiate/enhance bone formation following bone resorption (269). The
anabolic effect of systemically administered IGFBP-5 is the subject of the study reported in
Chapter Four.
(4) IGFBP Proteases
IGFBPs can be degraded to release their bound IGFs for local mitogenic action, and this
mechanism might play a large role in local regulation of IGF bioavailability (254). Several
IGFBP specific proteases have been identified (253). An IGFBP-4-specific protease has been
described (270, 271) and characterized (272, 273) in human serum that is IGF-II dependent. By
cleaving the IGFBP-4 its IGF inhibitory effect is ameliorated. Human bone cells and fibroblasts
in culture produce a protease relatively specific for IGFBP-5 (271, 274) that has decreased
activity in the presence of IGF. Other proteases produced by human bone cells have been
described which degrade not only IGFBPs but also other proteins as well, matrix metalloproteases
and plasmin (275).
b) Other Local Regulators
Many other local regulators of bone cell metabolism and turnover have been described:
for example Platelet Derived Growth Factor, Colony-stimulating Factors, Interleukin-1 and other
cytokines, Transforming Growth Factor (3, Bone Morphogenetic Proteins, Fibroblast Growth
Factors, and Tumor Necrosis Factor. Bone acts as a storage depot for many of these local
regulators, due to their affinity for calcium in hydroxyapatite (276). However, these other growth
factors will not be discussed in my dissertation, as the IGF system is the most important local
regulator pertinent to my studies.
F. Biochemical Markers of Bone Turnover
Bone is a dynamic tissue continuously being remodeled throughout life, and bone
formation is known to be coupled to bone resorption (191, 193, 194). Therefore markers of bone
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resorption and formation together are an index of bone turnover. Due to the remodeling process,
there is a lag time of 3-4 months between resorption and formation so that in disease or treatment
monitoring, this lag time must be taken into consideration (277). Use of biochemical markers is
based on the assumption that proteins or protein fragments released form bone cells or bone
matrix enter the circulation and that bone turnover accounts for a significant fraction of the blood
levels. In clinical and animal studies measuring bone formation and resorption using minimally
invasive methods provides a dynamic window on bone metabolism in vivo. Bone formation
markers are proteins produced specifically by bone forming osteoblasts, while bone resorption
markers are proteins liberated or produced specifically by bone resorbing osteoclasts. The
following section briefly describes some of the commonly used markers of bone formation and
bone resorption.
1. Biochemical Markers of Bone Formation
Active osteoblasts, bone forming cells, synthesize and secrete the extracellular matrix
proteins that make up the organic component of bone extracellular matrix. Several of these
proteins are relatively bone specific in expression and therefore can be used as markers of bone
formation. The established markers of bone formation are: 1) ALP, 2) osteocalcin, and 3)
procollagen peptide of type 1 collagen. These markers are discussed below.

a) ALP
In humans there are four ALPs encoded by four separate, but highly homologous genes:
placental, placental-like/germ cell, intestinal, and tissue nonspecific ALP (TNSALP). The first
three are relatively specific in tissue expression and are thermostable, while the TNSALP is
highly expressed in bone, liver and kidney, and at lower levels in other tissues (278) and less
thermostable. Bone specific isoforms of TNSALP are one of the hallmarks used to measure
differentiated osteoblast activity and therefore bone formation. ALP is an ectoenzyme located on
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the extracellular surface cell membrane, it is bound to the cell membrane by a phosphoinositol
moiety. It can be shed from the cell surface and this soluble ALP is found in the serum where it
can be measured (279, 280). The total ALP activity measurable in serum is derived mostly from
liver and bone sources and therefore made of hepatic and skeletal isoforms of TNSALP (281).
Assays involving heat denaturation, chemical inhibition of selective activity, gel electrophoresis,
wheat-germ agglutinin precipitation, and more recently specific antibodies can be used to
determine what percentage of the total serum ALP activity is derived from specific tissues (278).
In bone extracts however, ALP activity is exclusively derived from the osteoblasts and is
therefore a measure of osteoblast activity and bone formation. The functions of the different
ALPs, especially in bone, has been the subject of much research over the years (278). Bone
derived TNSALP is believed to play an important role in bone mineralization by increasing local
levels of inorganic phosphate, regulating local inhibitors of crystal growth, transporting
phosphate, acting as a calcium ATPase or calcium binding protein (282). TNSALP deficiency
results in hypophosphatasia and predominately affects skeletal and dental hard tissues (283).
ALP activity can be measured in serum and bone extracts using a para-nitrophenol phosphate
substrate (284).
ALPs identified from different mammal species are 80-85% homologous in amino acid
sequence and 90% homologous for cDNA. In mouse only three ALPs have been identified,
intestinal and tissue nonspecific ALP (which is also expressed in the placenta in the mouse) and a
third ALP, similar to placental ALP, is only expressed during embryological development (285).
In culture, mouse, rat and human cells show increased expression of the TNSALP gene when
treated with, cAMP and dexamethasone, while treatment with retinoic acid in rat osteoblasts
increased ALP, in human osteoblast it decreased ALP (286, 287). In human osteosarcoma cells,
TE85, 1,25 (OH)2 D increases TNSALP expression as well as its mRNA stability (288).
Immunoassays are not available for mouse skeletal isoforms of TNSALP; therefore traditional
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colormetric assays using a para-nitrophenol phosphate substrate are used to determine ALP
activity.
b) Osteocalcin
Osteocalcin is expressed almost exclusively by mature, active osteoblasts and as such is a
good marker of bone formation (289, 290). It is a y-carboxylated noncollagenous protein, making
up 10% of the noncollagenous proteins of bone extracellular matrix (291). Vitamin K is an
essential cofactor for this y-carboxylation of glutamic residues (gla) in osteocalcin and other ycarboxylated proteins (292). Proteins with gla residues have a high affinity for free calcium and
calcium-containing proteins; therefore osteocalcin is thought to play a role in the mineralization
of bone matrix, but the exact nature of that role is still undetermined. Osteocalcin expression
coincides with mineralization of the maturing osteoid, i.e. mineralization front (293), and its
concentration in bone extracellular matrix increases with hydroxyapatite deposition (294, 295).
Osteocalcin is coded for by a single gene in humans but by three genes in mouse, two of
which are exclusively expressed in mouse bone. However, osteocalcin null mice (both bone
specific osteocalcin genes were disrupted) have been shown to have greater bone formation but
no difference in bone mineralization compared to wildtype controls (296). It is important to note
that osteocalcin may also be released from bone matrix during osteoclastic resorption (297, 298);
therefore serum osteocalcin levels at any one time are a combination of osteoblastic/osteocytic
osteocalcin synthesis and osteoclastic osteocalcin release, so that serum osteocalcin levels are a
measure of bone turnover rather than pure bone formation. Osteocalcin gene expression shows
variable responses to growth factors and hormones depending on the system being used for the
assay, i.e. differentiated state of osteoblasts and time in culture (299). In vitro studies of human
and rat osteoblasts have shown that osteocalcin synthesis is up regulated by 1,25 (OH)2 D (300302) and basic FGF (303), but in general most factors down regulate osteocalcin production, such
as PTH (304), glucocorticoids (305, 306), and TGFp (307, 308). Osteocalcin gene expression in
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mouse is different than human or rat, such that 1,25 (OH)2 D down regulates gene expression in
mice (309).
Osteocalcin can be measured in human and mouse serum by specific RIA (310, 311).
Serum osteocalcin exists intact or as fragments. These fragments might be due to osteoblast
processing, degradation in the circulation and/or osteoclastic resorption (297, 298). RIAs that
measure intact and a large N-terminal fragment are more reliable as a measure of bone turnover
(282, 312, 313). Commercial ELISA assays are also available for clinical measurements.
Because osteocalcin gene expression is regulated by hormones such as 1,25 (OH)2 D and PTH, it
is possible that serum levels could reflect the effect of these hormones and might not reflect bone
formation changes per se. It is therefore necessary to confirm all serum osteocalcin results with
another marker of bone formation, such as ALP activity.
c) Byproducts of Type 1 Collagen Synthesis
Type 1 collagen is a triple helical, coiled-coil molecule made of two identical al chains
and a structurally similar a2 chain. The primary sequence of the a chain is unique in that every
third amino acid residue is glycine, which facilitates the coiling of the secondary structure. As
each nascent a chain is translocated into the endoplasmic reticulum the amino (N) terminal signal
sequence is clipped off by specific proteases. Each a chain consists of a short N terminal peptide,
a long central helical region and a short carboxy (C) terminal peptide. Posttranslation
modification of each a chain consists of hydroxylation and carboxylation of proline and lysine
residues, which allow for correct interaction between chains to form the mature collagen
molecule. Ascorbic acid (vitamin C) is essential for these modifications. Three a chains, two al
and one a2 chains, undergo alignment, initiated at the C terminal peptide end and in a zippering
motion form the helix of the mature collagen molecule in the direction of the N terminal peptide.
The helical shape is maintained by the formation of intra- and inter-chain disulfide bonds. These
helical procollagen molecules are targeted for secretion via the Golgi apparatus and secretary
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vesicles. At the surface of the cell, in the extracellular space, specific peptidases cleave the N and
C terminal propeptides forming the mature type 1 collagen molecule which spontaneously forms
fibrils with other mature type 1 collagen molecules (314). The cleavage of these propeptides
significantly decreases the solubility of the mature type 1 collagen and they can be measured in
the serum as an index of bone formation (315-317).
Type 1 collagen occurs in several connective tissues of the body, such as skin, tendon,
and teeth, but of these tissues only bone is routinely remodeled or turned over. Therefore the
majority of the type 1 collagen synthesis byproducts of C and N terminal propeptides found in
serum reflect the dynamic process of bone formation (317). Type 1 collagen synthesis is
increased by TGFP both in vitro (318) and in vivo (319); by IGF-I in vitro (320, 321) and in vivo
(322); and by IGF-II in vitro (320, 321, 323). Type 1 collagen synthesis is decreased by TNFa
(324-326); IL-1 (327, 328); FGF-2 (329-332); PTH (333, 334); vitamin D (335, 336) and
corticosteroids (337). PGE2has a biphasic effect on type 1 collagen production, at low doses it
increases synthesis, in part by stimulating IGF-I production (234, 338); and at high doses it
decreases collagen synthesis (339).
Clinically, measurement of C or N terminal propeptides of type 1 collagen are not as
useful as measurement of ALP or osteocalcin as a measure of bone formation (282). RIAs and
immunoassays have been developed to measure serum levels of C and N terminal propeptides in
human serum (340-342). No mouse assays are presently available for C or N terminal
propeptides of type 1 collagen.
2. Biochemical Markers of Bone Resorption
Osteoclasts, bone resorbing cells, are multinucleated cells derived from the monocyte
lineage. When activated to resorb bone, osteoclasts first demineralize the bone matrix and then
degrade and resorb the organic proteins (343). It is these degraded proteins and osteoclast
specific enzymes that can be used as specific markers of bone resorption. The established
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markers of bone resorption are 1) pyrodinolme/deoxypyrodinoline, 2) C and N terminal
crosslinked telopeptide of type 1 collagen, and 3) Tartrate Resistant Acid Phosphatase (TRAP).
Each of these markers are discussed below.
a) Degradation Products of Type 1 Collagen Resorption
Type 1 collagen makes up 95% of bone extracellular matrix proteins. Collagen
molecules, arranged head to tail in a quarter stagger alignment become highly cross-linked as the
collagen fibril matures. These cross-links are insoluble so that when mature type 1 collagen is
resorbed by osteoclasts, ring pyrodinoline or deoxypyrodinoline structures with or without
attached N or C-crosslinked terminal telopeptides are released into the circulation. These
insoluble degradation products then can be measured in serum and urine as an index of bone
resorption (317). These pyrodinolines are specific for mature collagenous tissues since newly
formed collagen has not become crosslinked. Type I collagen is not the only collagen to contain
pyrodinolines. Types II, III and IX also form crosslinks via pyrodinoline formation. Turnover of
type I collagen is higher in bone than in any other tissue. Pyrodinolines are also found in several
tissues other than bone, but the amount and type of crosslinking that occurs in these other tissues
appears to be different from bone, such that the ratios of pyrodinoline: deoxypyrodinoline is
relatively low in bone compared to other connective tissues (344). Due to the small size of
pyrodinoline rings, even when telopeptides are attached, they are quickly cleared by the kidney
and can therefore be measured clinically in urine samples. HPLC analysis of urine following acid
hydrolysis measures the total free pyrodinolines, but this is a tedious assay and commercially
available ELISA for both pyrodinoline and deoxypyrodinoline (345-347) are now available for
clinical use in urine. An ELISA assay is also available for clinical use to measure N-terminal
crosslinked telopeptides in urine (348, 349) as well as for C-terminal crosslinked telopeptides in
urine (350, 351) and in serum (342). Whenever a protein is being measured in urine, the fact that
it has had to pass through the liver and the kidney at least once must be taken into account, as

32

these are major sites of possible further degradation. All urine assay values must be standardized
for urinary creatinine. It must also be kept in mind that while resorption and formation are
coupled, any change in systemic bone formation can have a lag of several months as formation
follows resorption. For research, an RIA was developed for use in rat serum (Rat ICTP RIA,
DiaSorin, Inc., Stillwater, MN) and was also found to be valid for mouse serum but it is no longer
commercially available (352, 353).
b) Tartrate Resistant Acid Phosphatase
Acid phosphatase is a lysosomal enzyme. Isoenzymes of acid phosphatase are found in
bone, prostate, platelets, erythrocytes, and spleen. These isoenzymes can be partly separated by
electrophoresis. Osteoclast and macrophage acid phosphatase is resistant to tartrate while the
prostate isoform is not; hence the term tartrate resistant acid phosphatase or TRAP (343). The
exact nature of the role TRAP plays in bone resorption has been partially identified in TRAP null
mice that have minor disturbances in bone growth and remodeling. Therefore, TRAP is essential
for the optimal functioning of osteoclasts (354). Due to its relative specificity for osteoclasts,
TRAP activity in serum or bone extracts can be used as an index of bone resorption (343),
although bone extract TRAP is more specific than serum TRAP activity since the majority of the
TRAP in the extract is specifically bone derived. TRAP is unstable in frozen samples and serum
contains inhibitors of the enzyme. Therefore clinical use of serum TRAP as a marker for bone
resorption is limited. Development of a specific monoclonal antibody to the bone TRAP
isoenzyme might lead to an assay that is more useful as a marker of bone resorption (355). A
colorimetric assay measuring TRAP activity is routinely done in human or mouse serum using
para-nitrophenol phosphate as substrate and (L)-tartrate to inhibit other tartrate sensitive acid
phosphatase isoenzymes.
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G. Methods Used For Bone Mass Measurement
Changes in areal and volumetric bone density can be monitored noninvasively by two
radiological methods: dual-energy X-ray absorptiometry (DXA) and quantitative computed
tomography (QCT); and by ultrasound techniques (US). Because DXA is inexpensive, delivers a
low dose of radiation, is relatively fast and has been clinically available for a longer time, it is
more often utilized than is QCT in both human and animal studies (356). Densitometry is based
on differential attenuation of the X-ray beam as it passes through the object under examination
and measures bone and soft tissue and the apparent density of those areas. Ultrasound
measurement of bone density and architecture is a promising new screening technique for
osteoporosis.
1. Dual-energy X-ray Absorptiometry
DXA measures X-ray beam attenuation in a two dimensional matrix composed of pixels
and these measurements are expressed as grams of mineral per centimeter squared of sample
measured. DXA can measure not only mineralization of a given bone area and therefore areal
bone density, but also soft tissue composition such as lean muscle and fat. DXA is limited in that
it is a two dimensional view of the object and therefore has inbuilt errors related to architecture
and size differences of the various tissue types in the scan, i.e. DXA assumes that the thickness of
the soft tissue surrounding a bone is equal in all directions which is not usually the case. DXA
measurements are readily reproducible and it is easy to use making it ideal for clinical settings
(357). Hologic instruments use a simultaneous calibration system, where phantoms of known
density are continuously interposing the beam during measurement. DXA instruments modified
to measure small animals such as rats and mice are commercially available for use in research e.g.
Hologics PIXI.

34

2.

Quantitative Computed Tomography

QCT measures X-ray beam attenuation in a three dimensional matrix made of voxels and
uses a standard curve generated from scanning a phantom with known areas of density to
calibrate the machine and allow quantification of the unknown sample scan against this standard.
QCT allows the discrimination of cortical from trabecular bone and measures this density per unit
volume; therefore QCT produces a true density expressed as grams of mineral per cubic
centimeter of bone. Due to its ability to discriminate between cortical and trabecular bone, QCT
scans can also be analyzed to give geometric parameters such as periosteal circumference,
cortical thickness, and area. QCT measurements are readily reproducible and reliable. QCT
scans take a long time compared to DXA scans and deliver a larger dose of ionizing radiation, but
the advantage of cortical:trabecular differentiation is great. Specifically modified QCT
instruments for measurement of rodent appendages are available e.g. Norlands Research M XCT.
3.

Ultrasound

US measurement does not involve the use of ionizing radiation and therefore does not
require special licensing or monitoring procedures. It is safe and well tolerated by the public. US
measurements are mostly determined for the calcaneus, tibia or patella. The speed of the sound
waves in meters per second and the broad band ultrasound attenuation elucidate the elasticity,
stiffness, density, and bone architecture of the bone being examined. Normative data are still
being generated for US comparison, but preliminary data show great promise for US to be used in
screening for osteopenia (358).
//. Rationale and Hypothesis
This dissertation includes two studies related to regulation of skeletal changes in vivo
using a mouse model system. The first study looks at skeletal changes that occur before and
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during puberty, and the second evaluates bone formation following systemic treatment with
IGFBP-5. Rationale and specific aims for these two studies are discussed below.
1. Bone Accumulation Leading to Peak Bone Density
Osteoporotic fracture risk is closely correlated to areal bone density; therefore an
individual’s areal bone density is a reliable indicator of potential fracture risk. Many studies have
postulated that maximizing an individual’s attainment of peak bone mass, possibly even
surpassing their individual genetic potential might prevent development of osteoporosis and
fracture later in life. Based on the discussion of factors contributing to development of
osteoporosis earlier, it is apparent that the genetic component associated with development of
peak bone mass is a major player in the etiology of osteoporosis. We therefore hypothesized that
elucidation of differences in gene expression when comparing two inbred strains of mice, one
with -40% greater volumetric bone density than the other, would shed light on potential
mechanisms or pathways that contribute to these differences. The attainment of peak bone
density is greatly affected by postnatal, pubertal and postpubertal growth, so that the comparison
of these two strains of mice as they progress through these growth periods would contribute to
our understanding of the process of bone accretion and the differences in this process between
these mice that contribute to the bone density dimorphism.
To understand the potential mechanisms that contribute to the differences in peak bone density
between the two strains of mice, we proposed the following hypotheses:
1. differences in pubertal accretion of bone density contribute a large part to the difference in
peak bone density between the two strains of mice;
2. higher bone formation during postnatal growth in C3H/HeJ mice (C3 - high bone density
strain) than in C57BL/6J mice (B6 - low bone density strain) contributes in part to the
difference in bone density between these two strains;
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3.

serum IGF-I levels are higher in C3 mice contributing to the increased cortical thickness and
therefore increased bone mass of C3 mice compared to B6 mice;

4. bone turnover is lower in C3 mice contributing to the increased bone density in C3 mice
compared to B6 mice;
5.

sexual dimorphism in bone density seen in humans from puberty on, is also seen in these
mice, and becomes apparent during pubertal growth.

The above hypotheses were tested by the following specific aims:
1. quantify and compare the changes in bone density and bone geometric parameters of the
middiaphysis of the femur that occur during postnatal, pubertal and postpubertal growth in
C3 and B6 mice and when these differences between the two strains occur;
2. measure and compare the serum and bone extract bone formation markers during postnatal,
pubertal and postpubertal growth in C3 and B6 mice to determine the relative difference in
bone formation between these two strains;
3. measure and compare the serum IGF-I levels during postnatal, pubertal and postpubertal
growth in C3 and B6 mice to determine if IGF-I is associated with the differences in bone
density between the two strains;
4. measure and compare bone turnover markers in C3 and B6 mice to determine if bone
turnover is different between the two strains;
5. measure and compare differences in bone density, bone mass and bone geometric parameters
of male and female mice within each strain during postnatal, pubertal and postpubertal
growth to determine when sexual dimorphism becomes noticeable.
2. IGFBP-5: A Novel Bone Anabolic Factor
As discussed in the above section on regulators of bone turnover, the IGF system has been
shown to play a major role in bone metabolism. Within this system the diverse nature of the role
IGFBPs play is still being elucidated. Of the six IGFBPs, IGFBP-5 has some unique
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characteristics that may give it the ability to target bone specifically. The mitogenic role of
IGFBP-5 in vitro has been studied but nothing is known of its effect in vivo except that it is stored
in bone matrix and may play a role in the coupling of bone formation to resorption as discussed
above. To explore the role of IGFBP-5 in vivo we proposed the following hypotheses:
1. IGFBP-5 will increase bone formation in vivo similar to its effect on osteoblasts in vitro;
2. IGFBP-5 may mediate its bone forming effects in an IGF-I independent manner.
The above hypotheses were tested by the following specific aims:
1. measure bone formation markers in serum or bone extracts following systemic or local
treatment with IGFBP-5, respectively, to determine if IGFBP-5 treatment increases bone
formation;
2. measure serum IGF-I levels following treatment with IGFBP-5 to determine if IGFBP-5
administration increases circulating levels of IGF-I to mediate its anabolic effects on bone.
I.
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CHAPTER TWO

DETAILED METHODS AND PROCEDURES
A. Introduction
The methods and procedures used in the studies presented in Chapters Three and Four of
this dissertation are presented in detail in the following sections.
B. In Vitro Studies
Human osteoblast cell culture have been routinely prepared and used in our laboratory
(1). The individual protocols for the in vitro assays reported in Chapter Four are described below.
1.

Osteocalcin Production

For the osteocalcin experiments, MG63 (immortalized human osteosarcoma cells) or
primary human osteoblast cells were plated in 10% Bovine Calf Serum (CS) in Dulbecco’s
Modified Eagle’s Medium (DMEM) at 10,000 cells/ml in 24 well plates. 500 pi of this cell
suspension was plated in each well. After 24 hours the medium was changed to serum free
DMEM (0.01% Bovine Serum Albumin (BSA) in DMEM), and 2 hours later 0, 10, 100 or 300
ng/ml of rhIGFBP-5 with 10"8 M 1,25 (OH)2D, diluted in fresh DMEM, was added to the wells.
The conditioned medium (CM) was collected and the cultures terminated at 48 hours. The CM
was stored at -70 C until assayed for osteocalcin levels (see biochemical assay section below). At
termination of the plates, the attached cells were rinsed with 1 x Phosphate Buffered Saline (PBS)
to remove all remaining media. The cells were lysed with 0.03% Triton X-100. The Lowry
protein assay (see biochemical assay section below) was used to determine the total protein
content of these cell extracts which were used to normalize the osteocalcin values from the
radioimmunoassay (RIA).
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2. Alkaline Phosphatase Activity Determination
For the alkaline phosphatase (ALP) activity experiments, MG63 cells or primary human
osteoblasts were plated in 10% CS/DMEM in 96 well plates. 50 pi of 4,000 cells/ml cell
suspension was plated in each well. After 24 hours the medium was changed to serum free
DMEM, and 2 hours later 0, 1, 10 or 100 ng/ml of rhIGFBP-5 with and without 1,25 (OH)2D
diluted in fresh DMEM was added. The cultures were terminated at 72 hours. The attached cells
were rinsed with 1 x PBS to remove all remaining media and lysed with 0.03% Triton X-100.
The cell extract was used to determine ALP activity and total protein content (see biochemical
assay section below).
C. In Vivo Studies
All animals used in these studies were housed in a controlled environment with 12-hour
light/dark cycles at 70 °F with food and water ad libitum at the Animal Research Facility, Jerry L.
Pettis VA Medical Center (Loma Linda, CA). The experimental procedures performed in these
studies were in compliance with the NIH Guide for the Care and Use of Laboratory Animals. All
animals studies were reviewed and monitored by the Animal Studies Subcommittee at the Jerry
L. Pettis Veterans Administration Medical Center (Loma Linda, CA). The specific animal
protocols used in each study are described below.
1. Peak Bone Density Study (Chapter Three)
Inbred C3H/HeJ (C3) and C57BL/6J (B6) breeder mice were purchased from Jackson
Laboratory (Bar Harbor, ME). Upon receipt, the animals were allowed to acclimate to the new
environment for 7 days and were then bred to produce the pups used in this study. The female
breeders were housed individually several days before their due date and fed a breeders’ diet
(10% fat content, Harlan Teklad, Placentia, CA). The pups were weaned and weighed to the
nearest 0.1-gram on postnatal day 21 (ACCULAB V-600). At weaning, the pups were fed
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regular rodent chow (4% fat content, Harlan) and housed 4-5 pups per cage. Cages of female
pups were alternated with cages of male pups on each rack to eliminate uneven pheromone
distribution. Puberty in B6 female mice begins when serum estradiol increases on postnatal day
26 and vaginal opening occurs by day 31 (2). In humans, puberty starts roughly two years later in
males than in females, and therefore ends later in males than females (3). We calculated that in
mice, this difference would constitute a 2-3 day delay in males compared to females, so that
puberty should be completed by day 35 in males. Based on this data, we chose to collect pups at
day 7, 14 and 23 (before puberty starts), day 31 (at the end of puberty in females), day 35 (at the
end of puberty in males), and on days 42, 49 and 56. Pups were euthanized by C02 inhalation
(dry ice) using a desiccation chamber, followed by decapitation using a guillotine. Whole blood
was collected, allowed to clot before being centrifuged. The serum was skimmed off and stored
at -70°C until assayed for osteocalcin, IGF-I and IGF-II. The left femur was dissected free of soft
tissue keeping the condyles and femoral neck intact. The bone was then used for the bone extract
assay to determine bone specific ALP activity and bone size data. The right femur and proximal
tibia were dissected free and stored in 70% ethanol for volumetric bone density and geometric
parameter determination using a pQCT (Norland Medical Systems Incorporated, Fort Atkinson,
Wisconsin). Total protein bone extracts were derived from the freshly dissected left femora
(described under biochemical assay section). The right femora were dehydrated in 75% ethanol
and then allowed to dry out completely at 37°C. Once dry, the femoral length was measured
using a caliper (Dial Caliper, Mitutoyo Corporation, Japan) to the nearest 0.01mm and the bones
were weighed using a balance (Millibalance Model 7500, Electrobalance DTL, CAHN
Instruments Inc., Cerritos, CA) to the nearest 0.01 mg.
2. IGFBP-5 Study (Chapter Four)
7-week-old Balb/c or C3H/HeJ inbred mice were used for the in vivo experiments in
Chapter Four. In each experiment the treatment was injected subcutaneously at the nape of the
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neck of each mouse at the same time each day (9:00 am). 150 mM arginine-phosphate buffer, pH
7 was used as vehicle throughout the study. When IGF-I and IGFBP-5 were administered
together, the IGF-I and IGFBP-5 were mixed together and allowed to incubate at room
temperature for 1 hour before administration so as to form an IGF-I+IGFBP-5 complex before
administration. Size separation of this IGF-I+IGFBP-5 complex showed that >80% of the IGF-I
eluted in the 50 kDa fractions, suggesting that the majority of the IGF-I exists as a complex in the
IGF-I+IGFBP-5 treatment solution. The mice were euthanised with ethrane and decapitated with
a guillotine.
a) Serum Collection
Whole blood was collected in 50 ml tubes, centrifuged at 3500 rpm in a cold IEC Centra7R centrifuge and serum was skimmed off and stored at -70°C until assayed.

b) Femur Collection
Both femurs were dissected out of each carcass and cleaned of soft tissue, being careful
not to destroy the periosteum. Each bone was sectioned in the mid-diaphysis and rinsed in PBS at
4°C for 24 hours, followed by extraction in 0.01% Triton X-100 at 4°C for 72 hours. This bone
extract was used for the ALP activity measurements.
D. Bone Densitometry
Volumetric bone density and geometric parameters were determined using peripheral
quantitative computed tomograph (pQCT) with an XCT Research M (Norland Medical Systems,
Fort Atkinson, WI). pQCT has previously been validated as a reliable method of determining
volumetric bone density and geometric parameters in mice (4). Routine calibration was
performed daily with a defined standard (cone phantom) containing hydroxyapatite embedded in
lucite (Norland Medical Systems). Half-millimeter thick slices located at the mid-diaphysis were
scanned. The voxel size was set at 0.07 mm. Analysis of the scans was performed using the
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manufacturer-supplied software program (STRATEC MEDIZINTECHNIK GMBH Bone Density
Software, version 5.40C). Volumetric bone density along with geometric parameters was
estimated with Loop analysis. The threshold was set at 350 mg/cm3 for the 23-56 day old mice
and 150 mg/cm3 for the 7-14 day old mice in the cortical analysis. For cancellous analysis the
outer threshold was set at 250 mg/cm3 and the inner threshold at 300 mg/cm3 for 23-56 day old
mice, and 125 mg/cm3 and 150 mg/cm3 for 7 and 14-day-old mice, respectively. Because the
threshold value used in each analysis determines the area included which affects the calculation
of the parameters, only mineral content is comparable since it is independent of threshold values.
Therefore volumetric bone density and geometric parameters for day 7-14 and day 23-56 animals
must be analyzed separately.
E. Biochemical Assays
Biochemical assays that measure bone formation or resorption markers and growth factor
levels in cell or bone extract or serum provide an index of the relative proportion of formation to
resorption following specific treatment of the cells or animals or differences between different
types or strains of cells or animals. The biochemical assays used in the in vitro and in vivo
studies presented in this dissertation are described below.
1. Lowry Assay:
The protein concentration, which is a reflection of the cell number in each well was
determined using the Lowry Folin assay (5). At termination of the assay, the plates were rinsed
with 1 x PBS to remove all remaining media. The cells were lysed with 0.03% Triton X-100. A
protein standard curve made with BSA, with a range from 0.5 pg/well to 20 pg/well was used to
determine the protein concentration of each well. These values were used to normalize the
alkaline phosphatase activity values obtained from the alkaline phosphatase assay of the cell
extract in the in vitro studies.
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2. Bradford Protein Assay
The total protein content of the bone extract was determined using Bradford dye (BioRad,
Hercules, CA). A protein standard curve made with BSA, with a range from 0.5 pg/well to 20
pg/well was used to determine the protein concentration of each bone extract. These values were
used to normalize the alkaline phosphatase activity values obtained from the alkaline phosphatase
assay of the bone extract in the in vivo studies.
3. Alkaline Phosphatase Activity Assay
The alkaline phosphatase activity of the cell or bone extracts was determined by the
alkaline phosphatase assay developed by Farley et al. (6). At termination time, the cells were
rinsed with 1 x PBS to remove all media and the cells were lysed with 0.03% Triton X-100. A
paranitrophenol substrate was used to determine alkaline phosphatase activity; the change in
optical density was a measure of this activity. The alkaline phosphatase activity was a measure of
the effect of IGFBP-5 with or without 1,25 vitamin D3 on osteoblast differentiation in vitro or
IGFBP-5 treatment in vivo.
4. Bone Extract
The left femora were rinsed in IX PBS for 24 hours at 4°C and then transferred to 0.01%
Triton XI00 for 72 hours at 4°C to extract the membrane bound ALP from the osteoblast cell
surfaces. Bone specific ALP activity and total protein content (Bradford assay) were determined
for this extract.
5. Radioimmunoassay
Radioimmunoassay (RIAs) are routinely used to measure protein levels in serum, urine or
protein extracts. Immunoassays work on the principle of competitive binding. A fixed
concentration of labeled tracer competes with an unknown concentration of the protein of interest
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in the sample (or with a known concentration of unlabeled standard) for binding to a specific
antibody raised against an epitope of the protein of interest. This primary antibody is first added
to the sample or standard diluted in RIA buffer and then the labeled tracer is added. This mixture
is allowed to incubate for several hours to ensure saturation of the primary antibody. A
secondary antibody, raised against the Fc fragment of IgG from the animal species the primary
antibody was developed in, is added and the mixture is again allowed to incubate. A precipitating
agent, such as polyethylene glycol (PEG), is added to this mixture and the RIA tubes centrifuged
to pull down the antibody-protein sandwich pellet. The supernatant is decanted and the tubes
swabbed to ensure no unbound tracer contaminates the pellet. Counts per minute (CPM) are
measured in the appropriate counter, i.e. gamma counter for I125 labeled tracer, and compared to
the standard curve that was made up using known concentrations of the protein of interest. The
concentration of the protein of interest is inversely proportional to the CPM because the unlabeled
sample competes with the labeled tracer for binding to the primary antibody. In this dissertation,
measurement of IGF-I and -II, IGFBP-5, osteocalcin and carboxyterminal cross-linked
telopeptide of type I collagen was done by specific RIA. Specific antibodies and procedures for
each individual assay are described below.
a) Separation of IGFs from IGFBPs
Because IGFBPs produce artifacts in IGF RIAs, complete separation of the IGFBPs from
the IGFs is necessary in order for the IGF determinations to be valid (7). This method used sizeexclusion chromatography under acidic conditions for removal of IGFBPs from IGFs in serum
and conditioned medium before IGF RIAs were performed.
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(1) Biospin Protocol
(a) Preparation of columns:
1. In a flask, hydrate lOg of Bio-gel P-10 (Bio-Rad Laboratories, Hercules, CA) in 150 mL of
1M acetic acid and 0.1M NaCl. Allow to stand for 4 hours or overnight. Add 1.5g BSA and
let it dissolve without shaking. After the BSA has dissolved, mix the beads gently and allow
the beads to incubate for 4 hours or overnight. De-gas for 10-15 minutes, swirling the flask
occasionally.
2. Put an additional dot filter (glass fiber filter G6, Fisherbrand, Cat. No: 09-804-55A, soaked in
1M acetic acid containing 0.1M NaCl overnight) on top of the original filters in the Bio-Spin
columns (Bio-Spin Disposable Chromatography Columns, Bio-Rad Laboratories, Hercules,
CA).
3. Pipette 2 mL gel slurry into the empty Bio-Spin column and let stand until there is room to
add an additional 1 mL of gel (total volume of gel slurry is therefore 3 mL). The bead height
is about 4 cm. Cap the column at both ends and store at room temperature until ready to use.
Don’t let the columns go dry!!
4. Before using, uncap and place the column in a polypropylene collection tube and centrifuge
for 7 minutes at 3000 rpm (Beckman T6J centrifuge).
(b) Preparation of the Sample:
For serum samples: mix 50pl of serum with 200]ul of 1.25M acetic acid with 0.125M
NaCl and incubate for 10 minutes.
For serum controls: to the high and low serum controls add lOOpl 1.25M acetic acid with
0.125M NaCl and incubate for 10 minutes.
For conditioned medium (CM) samples: Speedvac 0.625 mL CM till dry and reconstitute
in 62.5pl of 1.25M acetic acid with 0.125M NaCl.
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(c) Separation ofIGF’s from IGFBPs:
Label the column and apply 50jul of sample and controls carefully to the center of the
column. Centrifuge for 7 minutes at 3000 rpm. Add 50pl of 1M acetic acid containing 0.1M
NaCl and centrifuge again for 7 minutes. Add 1 ml of 1M acetic acid containing 0.1M NaCl to
the column and place column in a labeled collection tube (use a coated tube to collect the IGF’s
from CM). Centrifuge for 9 minutes to elute IGFs. Rinse column with 500pi of 1M acetic acid
containing 0.1M NaCl and centrifuge for 9 minutes. Final collection volume = 1.5 ml.
The IGF pool derived from serum samples can be store at 4°C overnight or at -20°C (up
to 4 weeks) until assayed. The IGF pool derived from CM samples must be speedvac’ed and
stored in tubes at 4°C until assayed.
(d) Preparation of IGF pools for RIA
For serum samples:
1. For IGF-I RIA: transfer 50pl of IGF pool to polypropylene tubes in duplicate and neutralize
with 50pl of 1.2M Tris base prior to IGF-I assay. Multiply the IGF-I values determined by
RIA by 300 to get the final concentrations in ng/ml.
2. For IGF-II RIA: transfer 25pl of IGF pool to polypropylene tubes in duplicate and neutralize
with 25pl of 1.2M Tris base. Add 50pl of IGF-II buffer to each tube to bring volume up to
lOOpl prior to IGF-II assay. Multiply the IGF-II RIA values by 600 to get the final
concentration in ng/ml.
For CM samples:
Reconstitute the IGF pool with 250pl of 20 mM acetic acid, sonicate for 1 minute and use 50pl in
duplicate for IGF-I and IGF-II assays. Divide the IGF values determined by RIA by 2 to get the
final concentrations in ng/ml.
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(e) Recipe for coated tubes
500 ml
2.3 g
0.5 g

DMEM
HEPES
BSA

1. Make up binding medium and adjust the pH to 7.4 with 5N NaOH. Warm up this medium to
37 ° C in the water bath and sterile filter it.
2. Add 2 ml of the sterile, warm medium to 250 polypropylene tubes.
3. Cover with parafilm and incubate at 37°C for 3 hours in a 37°C incubator.
Suction off this binding medium and store tubes at 4°C for up to 3 weeks.

b) IGF-I Radioimmunoassay
IGF-I was measured by specific RIA as previously described (8) following separation of
the IGFBPs as described above. The cross-reactivity of IGF-II in the IGF-I RIA was less than
0.5%. The sensitivity of the IGF-I RIA was less than 50 ng/L and the intra- and inter-assay
coefficients of variation were less than 10%.
(1) IGF-I RIA Protocol
(a) Day 1
1. Label polypropylene tubes and place them in a RIA rack and set aside. Prepare samples as
described in biospin protocol.
2. Prepare RIA buffer if necessary.
3. Label 9 sets of polypropylene tubes (7/8, 9/10, 11/12, 13/14, 15/16, 17/18, 19/20, 21/22 and
23/24) for the standard curve. Create a standard curve by preparing the following standard
dilutions in series from 62.5 ng/mL IGF-I stock (1:10 dilution) down to 0.025 ng/mL. Vortex
each tube after adding standard to ensure a homogeneous mix.
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Tube #
23/24
21/22
19/20
17/18
15/16
13/14
11/12
9/10
7/8

Total Volume
(^1)
500
250
250
250
250
250
250
250
500

Concentration
(ng/mL)
6.25
3.13
1.56
0.78
0.39
0.195
0.098
0.049
0.025

Amount of IGF-I
(^tl)
50 from stock
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above

Amount of buffer
(^1)
450
250
250
250
250
250
250
250
250

4. Pipette lOOpl of each of the standard curve dilutions in the corresponding RIA tubes and add
200pl of RIA buffer to bring the volume up to 300pl Also add 400pl of RIA buffer to tubes
3+4, and 300pl of the RIA buffer to tubes 5 + 6.
5. Pipette lOOpl of each reconstituted high control into tubes 25/26 and low control into tubes
27/28 and add 200|li1 of the RIA buffer to bring the volume up to 300pl
6. Pipette 50pl of your sample in duplicate and add 250pl of the RIA buffer to bring the volume
up to 300pl.
7. Dilute the primary rabbit anti-IGF-I to 1/3000 ratio. The stock is already diluted 1/10 so it
will be a 1/300 dilution. Total volume needed is (lOOpl x the number of tubes). Add lOOpl
of this primary antibody dilution to all tubes except #1-4.
8. Make tracer (125I) dilution. You need 40,000 counts per lOOpl. Look at the date it was
prepared and use the decay chart to find the decay factor to use in the equation.
(40,000/counts in lOOpl x decay factor) x total volume = volume of tracer needed
Then make up the dilution using RIA buffer to make a total volume of (lOOpl x the number
of tubes). Use lOOpl to measure CPM to check your dilution. Adjust for any discrepancy
and add lOOpl of this dilution to all tubes.
9. Cover with aluminum foil, label clearly and store in the cold room overnight.
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(b) Day 2
1. Make up the secondary antibody solution using:
Normal rabbit serum in a 1/20 dilution
Number of tubes x lOOpl = total volume
—>• Total volume/20 dilution = volume of stock needed
Goat anti-rabbit in a 1/20 dilution
Number of tubes x 400pl = total volume
—» Total volume/20 dilution = volume of stock needed
Combine these two together in a beaker and aliquot 500 pi of this mixture into each tube
except tube #1+2.
2.

Add 200pl of 8% PEG to tubes #3 and up.

3.

Cover the racks with tinfoil and put on shaker/vortex to mix each tube gently and then
incubate for 2-4 hours at room temperature. There should be a visible precipitate at the end
of this time.

4.

Load the centrifuge buckets making sure to balance each pair. Centrifuge the tubes at
maximum speed for 25-30 minutes. DO NOT CENTRIFUGE THE TOTAL COUNT
TUBES (#1/2)!!!

5.

Cover Styrofoam blocks with paper towels for blotting the tubes. In one smooth motion, pour
out the supernatant in the l25I liquid waste bucket and place the centrifuge holder upside
down on the towel covered blocks. Allow to drain for 5 minutes.

6. Lay the buckets with the tubes still inside on their sides and swab the lips of the tubes initially
to remove the excess drops of supernatant before it dries. Now swab out each tube, staying
clear of the pellet. Put the tubes into the counter racks in the correct order.
7.

Count the tubes for 1 minute in the gamma counter.
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(c) RIA Buffer
0.1% Fluka BSA
Protamine sulfate
EDTA
NaN3
NaH2P04 (monobasic)
ddH20
pH

1 gm
0.2 gm
3.72 gm
0.2 gm
4.8 gm
11
4.5

c) IGF-II Radioimmunoassay
IGF-II was measured by specific RIA as previously described (8) following separation
from the IGFBPs as described above. The cross-reactivity of IGF-I in the IGF-II RIA was less
than 2%. The sensitivity of the IGF-II RIA was 0.1 pg/L and the intra- and inter-assay
coefficients of variation were less than 10%.
(1) IGF-II RIA Protocol
(a) Day 1
1.

Label polypropylene tubes and place them in an RIA rack and set aside.

2.

Prepare RIA buffer if necessary.

3.

Label 9 sets of polypropylene tubes (7/8, 9/10, 11/12, 13/14, 15/16, 17/18, 19/20 and 21/22)
for the standard curve. Create a standard curve by preparing the following standard dilutions
in series from 62.5 ng/mL IGF-II stock (1:10 dilution) down to 0.025 ng/mL. Vortex each
tube after adding standard to ensure a homogeneous mix.
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Tube #
23/24
21/22
19/20
17/18
15/16
13/14
11/12

Total Volume
(^1)
500
250
250
250
250
250
250

9/10
7/8

250
500

Concentration
(ng/mL)

Amount of IGF-II
(^)

(HD

6.25
3.13
1.56
0.78
0.39
0.195
0.098
0.049
0.025

50 from stock
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above

450
250
250
250
250
250
250
250
250

Amount of buffer

4. Pipette lOOpl of each of the standard curve dilutions in the corresponding tubes and add
200pl of IGF-II buffer to bring the volume up to 300pl. Also add 400pl of IGF-II buffer to
tubes 3 + 4, and 300pl of the of IGF-II buffer to tubes 5 + 6.
5. Put lOOpl of each of reconstituted high control in tubes 25/26 and low control in tubes 27/28
and add 200pl of the IGF-II buffer to bring the volume up to 300|nl.
6. Pipette SOpl of your sample samples in duplicate and add 250pl of the IGF-II buffer to bring
the volume up to 300pi.
7. Dilute the primary mouse anti-IGF-II to 1/3000 ratio. The stock is already diluted 1/10 so it
will be a 1/300 dilution. Total volume needed is (lOOpl x number of tubes). Add lOOpl of
this primary antibody to all tubes except #1-4.
8. Make tracer (125I) dilution. You need 40,000 counts per lOOpl. Look at the date it was
prepared and use the decay chart to find the decay factor to use in the equation.
(40,000/counts in lOOpl x decay factor) x total volume = volume of tracer needed
Then make up the dilution using RIA buffer to make a total volume of (lOOpl x # of tubes).
Use lOOpl to measure CPM to check your dilution. Adjust for any discrepancy and add
lOOpl of this dilution to all tubes.
9. Cover with aluminum foil, label clearly and store in the cold room overnight.
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(b) Day 2
1. Make up the secondary antibody:
Normal mouse serum in a 1/10 dilution
Number of tubes x lOOpl = total volume
-» Total volume/10 dilution = volume of stock needed
Goat anti-mouse in a 1/10 dilution
Number of tubes x 400|ul = total volume
^ Total volume/20 dilution = volume of stock needed
Combine these two together in a beaker and aliquot 500pl of this mixture into each tube
except tube #1+2.
2.

Add 200pi of 8% PEG to tubes #3 and up.

3.

Cover the racks with tinfoil and put on shaker/vortex to mix each tube gently and then
incubate for 2-4 hours at room temperature. There should be a visible precipitate at the end
of this time.

4.

Load the centrifuge buckets making sure to balance each pair. Centrifuge the tubes at
maximum speed for 25-30 minutes. DO NOT CENTRIFUGE THE TOTAL COUNT
TUBES (#1/2)!!!

5.

Cover Styrofoam blocks with paper towels for blotting the tubes. In one smooth motion, pour
out the supernatant in the 125I liquid waste bucket and place the centrifuge holder upside
down on the towel covered blocks. Allow to drain for 5 minutes.

6. Lay the buckets with the tubes still inside on their sides and swab the lips of the tubes initially
to remove the excess drops of supernatant before it dries. Now swab out each tube, staying
clear of the pellet. Put the tubes into the counter racks in the correct order.
7.

Count the tubes for 1 minute in the gamma counter.
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(c) RIA Buffer
0.1% Fluka BSA
Protamine sulfate
EDTA
NaN3
NaH2P04 (monobasic)
ddH20
pH

1 gm
0.2 gm
3.72 gm
0.2 gm
4.8 gm
11
4.5

d) IGFBP-5 RIA
Serum IGFBP-5 was measured by specific RIA using rhIGFBP-5 as standard and tracer
as previously described (9). None of the other high affinity IGFBPs cross-react with the
antiserum used in this assay. The sensitivity of the IGFBP-5 RIA is <5 ng/ml and the intra- and
interassay coefficients of variation are less than 8%.
(1) IGFBP-5 RIA Protocol
(a) Day 1
1. Fabel polypropylene tubes and place them in an RIA rack and set aside.
2. Prepare RIA buffer if necessary.
3. Fabel 9 sets of polypropylene tubes (7/8, 9/10, 11/12, 13/14, 15/16, 17/18, 19/20 and 21/22)
for the standard curve. Create a standard curve by preparing the following standard dilutions
in series from 2.2 mg/mP IGFBP-5 stock (1:10 dilution) down to 1.9 ng/mF. Vortex each
tube after adding standard to ensure a homogeneous mix.
Tube #

Total Volume
(pl)

Concentration
(ng/mF)

21/22
19/20
17/18
15/16
13/14
11/12
9/10
7/8

500
250
250
250
250
250
250
500

250
125
62.5
31.2
15.6
7.8
3.9
1.9

Amount of IGFBP-5
(pl)
57 from stock
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above
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Amount of buffer
(Pi)

443
250
250
250
250
250
250
250

4.

Pipette lOOpl of each of the standard curve dilutions in the corresponding tubes and add
200pl of RIA buffer to bring the volume up to 300pl Also add 400pl of RIA buffer to tubes
3 + 4, and 300pl of the of RIA buffer to tubes 5 + 6.

5.

Pipette lOOpl of each of the reconstituted high control in tubes 23/24, low control in tubes
25/26, high serum control in the second last two tubes, and low serum control in the last two
tubes. Add 200pl of the RIA buffer to bring the volume up to 300pl.

6. Pipette lOOpl of your sample in duplicate and add 200pl of the RIA buffer to bring the
volume up to 300pi.
7.

Dilute the primary guinea pig anti-IGFBP-5 to 1/1000 ratio. The stock is already diluted 1/10
so it will be a 1/100 dilution. Total volume needed is (lOOpl x number of tubes). Add lOOpl
to all tubes except #1-4.

8. Make tracer (125I) dilution. You need 40,000 counts per lOOpl. Look at the date it was
prepared and use the decay chart to find the decay factor to use in the equation.
(40,000/counts per lOOpl x decay factor) x total volume = volume of tracer needed
Then make up the dilution using RIA buffer to make a total volume of (lOOpl x number of
tubes). Take lOOpl to measure the counts to check your dilution. Adjust for any discrepancy
and add lOOpl of this dilution to all tubes.
9. Cover with aluminum foil, label clearly and store in the cold room overnight.
(b) Day 2
1. Make up the secondary antibody:
Normal guinea pig serum at 1/10 dilution
Number of tubes x lOOpl = total volume
-» Total volume /20 dilution = volume of stock needed
Goat anti-guinea pig at 1/10 dilution
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Number of tubes x 400jil = total volume
-» Total volume/20 dilution = volume needed of stock
Combine these two together in a beaker and aliquot 500 ql of this mixture into each tube
except tube #1 + 2.
2. Add 200(il of 8% PEG to tubes #3 up.
3.

Cover the racks with aluminum foil and put on shaker for 2-4 hours at room temperature.
There should be a visible precipitate at the end of this time.

4.

Load the centrifuge buckets, making sure to balance each pair. Centrifuge the tubes at
maximum speed for 25-30 minutes. DO NOT CENTRIFUGE THE TOTAL COUNT
TUBES (#1/2)!!!

5. Cover Styrofoam blocks with paper towels for blotting the tubes. In one smooth motion, pour
out the supernatant in the 125I liquid waste bucket and place the centrifuge holder upside
down on the towel covered blocks. Allow to drain for 5 minutes.
6. Lay the buckets with the tubes still inside on their sides and swab the lips of the tubes initially
to remove the excess drops of supernatant before it dries. Now swab out each tube, staying
clear of the pellet. Put them into the counter racks in the correct order.
7.

Count the tubes for 1 minute in the gamma counter.
(c) RIA Buffer

0.1% Lluka BSA
Protamine sulfate
EDTA
NaN3
NaH2P04 (monobasic)
ddH20
pH

1 gm
0.2 gm
3.72 gm
0.2 gm
4.8 gm
11
4.5
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e) Osteocalcin Assay
Osteocalcin levels in serum were measured by specific RIA (10). The mouse osteocalcin
RIA had coefficients of variation <8% interassay variability.
(1) Mouse Osteocalcin RIA Protocol
1. Label polypropylene tubes and place them in an RIA rack and set aside.
2. Prepare citrate buffer if necessary.
3. Label 7 sets of polypropylene tubes (7/8, 9/10, 11/12, 13/14, 15/16, 17/18, and 19/20) for the
standard curve. Create a standard curve by preparing the following standard dilutions in
series from 25 ng/mL osteocalcin standard stock down to 0.39 ng/mL. Vortex each tube after
adding standard to ensure a homogeneous mix.

19/20
17/18
15/16
13/14
11/12

Total Volume
(Pi)
250
250
250
250
250

9/10
7/8

250
500

Tube #

Concentration
(ng/mL)

Amount of IGF-I
(pl)
250 from stock
250 from above
250 from above
250 from above
250 from above
250 from above
250 from above

25
12.5
6.25
3.125
1.56
0.78
0.39

Amount of buffer
(pl)

250
250
250
250
250
250
250

4. Pipette lOOpl of each of the standard curve dilutions in the corresponding tubes. Add 400|ul
of RIA buffer to tubes 3 + 4, and 300pl of the citrate buffer to tubes 5 + 6.
5. Pipette 100pl of each of the reconstituted high control into tubes 21/22 and the low control
into tubes 23/24.
6. Pipette 5 pi of sample in duplicate and add 95 pi of the citrate buffer to bring the volume up to
lOOpl.
7. Dilute the primary rabbit anti-osteocalcin to 1/2000 ratio. Total volume needed is (lOOpl x
number of tubes). Add lOOpl to all tubes except #1-4.
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8. Make tracer (125I) dilution. You need 40,000 counts per lOOpl Look at the date it was
prepared and use the decay chart to find the decay factor to use in the equation.
(40,000/counts per lOOpl x decay factor) x total volume = volume of tracer needed
9. Then make up the dilution using citrate buffer to make a total volume of (lOOpl x number of
tubes). Use lOOpl to measure CPM to check your dilution. Adjust for any discrepancy and
add lOOpl of this dilution to all tubes.
10. Cover with aluminum foil, label clearly and incubate at room temperature for 2 hours +15
minutes.
11. Make up the secondary antibody:
Normal rabbit serum at 1/10 dilution
number of tubes x lOOpl = total volume
—» total volume /20 dilution = volume of stock needed
Goat anti-rabbit at 1/10 dilution
number of tubes x 400pl = total volume
—» total volume/20 dilution = volume needed of stock
Combine these two together in a beaker and aliquot 500pl of this mixture into each tube
except tube #1 + 2.
12. Add 200pl of 8% PEG to tubes #3 and up.
13. Cover the racks with aluminum foil and incubate at room temperature for 90 minutes ±10
minutes.
14. Load the centrifuge buckets, making sure to balance each pair. Centrifuge the tubes at 2500 x
g for 20 minutes. DO NOT CENTRIFUGE THE TOTAL COUNT TUBES (#1/2)!!!
15. Cover Styrofoam blocks with paper towels for blotting the tubes. In one smooth motion, pour
out the supernatant in the 125I liquid waste bucket and place the centrifuge holder upside
down on the towel covered blocks. Allow to drain for 5 minutes.
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16. Lay the buckets with the tubes still inside on their sides and swab the lips of the tubes initially
to remove the excess drops of supernatant before it dries. Now swab out each tube, staying
clear of the pellet. Put them into the counter racks in the correct order.
17. Count the tubes for 1 minute in the gamma counter.
18. Multiply the values obtained in ng/ml by a factor of 48 to get the final concentration in ‘ng/ml
of mouse osteocalcin’.
(a) Citrate Buffer
Citric Acid (monohydrate)
Na Azide/Thimersol
BSA
Tween 20
ddH20
pH
Store at 4°C.

f)

10.507 g
1-0 g
5.0 g
0.5 g
1 liter
7.0

Carboxyterminal Cross-linked Telopeptide Assay

Carboxyterminal cross-linked telopeptide of type I collagen was measured in the mouse
serum according to the manufacturers instructions using a Rat ICTP RIA Double Antibody Kit
purchased from DiaSorin (Stillwater, Minnesota). The sensitivity of this assay is 0.5 pg/L and
the mean recovery was 108.5%. The intra- and interassay coefficients of variation are less than
11% (11).
6.

Western Immunoblot for IGFBP-5

Serum from animals in experiment 4 of the IGFBP-5 in vivo study, were subjected to
electrophoresis on a 12% acrylamide gel under denaturing conditions, transferred to a
nitrocellulose membrane and the membrane was immunoblotted for IGFBP-5 using the same
antibody used in the IGFBP-5 RIA (see above).
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a) SDS-PAGE Protocol
1. Prepare a 12% SDS-PAGE gel.
2. Load 5 pi of serum per lane, 10 ng of positive control and 10 pi of the molecular weight
marker. Record the loading order and the molecular weight marker control #.
Electrophoresis at 100 V for 2 hours or until the samples reach the bottom of the gel.
Measure and record the height of molecular weight marker bands on the gel.
Protein
Myosin
P-galactasidase
Bovine serum albumin
Ovalbumin
Carbonic Anhydrase
Soybean trypsin inhibitor
lysozyme
aprotinin

Molecular Weight

200,000
114,000
82,000
49.300
34,900
28,800
20.300
7,000

3. Transfer to a nitrocellulose 0.2 pm (Bio-Rad Laboratories, Hercules, CA) membrane, in
transfer buffer, one hour at 0.2 mA, which is about 30-40 volts, at 4° C.
4. Remove the blot from the transfer apparatus and immediately place in a bath with double
distilled water (ddH20) and rinse for 10-15 minutes.
5. Decant ddH20 and add blocking buffer (0.5% dry milk in wash buffer). Block for 1 hour at
room temperature.
6. Decant blocking buffer and place membrane in a plastic bag with Guinea Pig anti-IGFBP-5
primary antibody diluted 1/1000 in blocking buffer (10 ml). Incubate for one hour at room
temperature.
7. Decant primary antibody solution and place membrane in wash buffer (TBS-T buffer). Wash
by agitation for 50 minutes, change the wash buffer every 10 minutes. Decant the wash
buffer.
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8.

Put secondary antibody (anti-guinea pig, horseradish peroxidase linked whole antibody for
the Guinea Pig anti-IGFBP-5, and anti-guinea pig IgG) diluted 1/2000 in blocking buffer (10
ml) in a bag and place membrane in this solution. Seal membrane in making sure there are no
air bubbles. Incubate for one hour at room temperature.

9. Decant secondary antibody solution and place membrane in wash buffer (TBS-T buffer).
Wash by agitation for 50 minutes, change the wash buffer every 10 minutes. Decant the
wash buffer.
10. Tape a layer of plastic wrap tightly to the inside of the cassette so that there are no bubbles
and tares.
11. Mix detection solutions 1 and 2 (Pierce Super Signal) in a 1:1 ratio (7 ml:7 ml). Pour into a
bath and place the membrane protein side down for 1 minute while gently rocking left to
right. Blot the membrane dry.
12. Place the membrane protein side up on the plastic wrap in the cassette, cover with a second
piece of plastic wrap, excluding all the air bubbles. Close the cassette.
13. In the dark room, switch off the lights, remove a sheet of x-ray film from the box, open the
cassette and position the film in the cassette. Close the cassette and start the timer for 2.5
minutes. Close the x-ray film box and turn off the lights.
14. When time is up, switch off the lights, open cassette, bend top right hand comer of x-ray film,
send the x-ray film through the developer, once the indicator light comes on, switch the lights
back on.
15. Based on the under or over exposure, repeat step 18 and 19.
12% SDS-PAGE Running Gel
1.

Set up mini-gel apparatus and check for leaks.
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2. Make the separating gel in a 50 ml tube:
Acrylamide Monomer Solution (30% T, 2.7% C)
buffer (1.5M Tris-HCl, pH 8.8)
10% SDS
ddH20
3.

12 ml
7.5 ml
0.3 ml
10.5 ml

Swirl contents lightly, attach vacuum to top of tube and degas for 2 minutes.

4. In fume hood add 10 pi TEMED and then add a small amount of Ammonium persulfate,
swirl.
5. Immediately cast the gel, filling the apparatus 2/3rds of the way full. Cover with ddH20.
6. Make stacking gel:
Acrylamide Monomer Solution (30% T, 2.7% C)
buffer (1.5M Tris-HCl, pH 8.8)
10% SDS
ddH20
7. Let stacking gel sit until you are ready to cast it.

1.33 ml
2.5 ml
0.1 ml
6.1 ml

8. Once the separating gel is set, pour off the water, aspirating the last few drops with a syringe.
9. In fume hood add 5 pi TEMED and then add a small amount of ammonium persulfate, swirl.
10. Add stacking gel on top of the separating gel until full, center comb and inset it to the desired
depth. Add more stacking gel if there are any deficiencies. Let it set.
11. When the stacking gel is set, take out combs very gently. Load the sample and molecular
weight markers.
12. Snap mini-gels out of apparatus and attach to voltage plugs.
13. Very gently, fill the middle section to the top with running buffer.
14. Fill the outside off the apparatus 2/3rds full with running buffer.
15. Electrophoresis at 100 V for 2 hours or until the samples reach the bottom of the gel.
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Running Buffer
Trizma Hydrochloride
Glycine
10% SDS
ddH20

12 g
57.6 g
40 ml
~41

Stir to dissolve.
Transfer Buffer
TrisHCl
glycine
methanol
ddH20
total volume
pH

12 g
57.6 g
600 ml
3400 mL
4L
8.8
TBS-T Buffer (wash buffer)
9.6 g
32 g
4 mL
15.2 mL
3980 mL
4L

TrisHCl
NaCl
0.1% Tween 20
1MHC1
ddH20
total volume
pH

7.4

7.

Gel-filtration of IGFBP-5 + IGF-I Complex

To evaluate the extent of complex formation between IGF-I and IGFBP-5, an aliquot of
the IGF-I + IGFBP-5 treatment solution used for the IGFBP-5 in vivo studies was subjected to
size separation using Sephradex G75 (Sigma-Aldrich, St. Louis, Missouri). The proteins were
eluted with PBS containing 0.1% BSA and 0.02% sodium azide, pH 7.2. The fractions were
collected and assayed for IGF-I after separation of IGF-I from the IGFBPs by a biospin protocol
(see above). Molecular weight standards were used to determine the elution position of the 40
kDa (IGF-I + IGFBP-5 complex) and 7.7 kDa (IGF-I) proteins.
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A. Abstract
Previous studies have shown that 60-70% of peak bone density is genetically determined.
The higher the peak bone density, the less likely an individual is to eventually develop
osteoporosis. Therefore, the amount of bone accrued during postnatal and pubertal growth is an
important determining factor in the development of osteoporosis. We evaluated the contribution
of skeletal changes before, during and after puberty to the development of peak bone density in
C3H/HeJ (C3H) and C57BL/6J (B6) mice. Volumetric bone density and geometric parameters at
the middiaphysis of femora were measured by pQCT from day 7 through 56. Additionally,
biochemical markers of bone turnover in serum and bone extracts were quantified. Both B6 and
C3H mice showed similar body and femoral weights. B6 mice had greater middiaphysial total
bone area and thinner cortices than did C3H mice. Within strains, males had thicker cortices than
did females. C3H mice accumulated more mineral throughout the study, with the most rapid
accumulation occurring postnatally (day 7-23) and during pubertal maturation (day 23-31). C3H
mice had higher volumetric bone density as early as day 7, with males tending to have a higher
volumetric bone density than did females. Higher serum IGF-I was present in C3H mice
postnatally until day 23. Until day 35, B6 mice had significantly higher serum osteocalcin.
Alkaline phosphatase was found to be significantly higher in the bone extract of C3H mice until
day 23. These data are consistent with and support the hypothesis that the greater amount of bone
accrued during postnatal and pubertal growth in C3H mice compared to B6 mice may be due to
increased cortical thickness caused by increased endosteal bone formation and decreased
endosteal bone resorption.
Key words: bone density, puberty, IGF-I, osteocalcin, C3H/HeJ and C57BL/6J mice
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B. Introduction
The risk of developing senile osteoporosis in men and postmenopausal osteoporosis in
women is in a large measure determined by the amount of bone mass accumulated during the
active growth phases early in life. This accumulation of bone mass determines the peak bone
density attained during the 3rd decade of life (1, 2) and may play a role in the rate of bone loss
during the later part of life. About 60-70% of peak bone density is genetically determined (3),
and 40-50% of peak bone density is accumulated during puberty (4). Elucidation of the
mechanisms regulating this dramatic increase in skeletal mass during puberty is important in the
effort to identify potential preventive or interventive measures that would lower the risk of
developing osteoporosis.
In humans, peak bone density is attained between 20-30 years of age (1, 2). The most
rapid accumulation in bone mass occurs in postnatal growth, from birth to roughly 3 years of age,
and during puberty, from 12-18 years of age (5). This increase in bone mass closely correlates
with an increase in body weight and height. Puberty is initiated 2 years earlier in girls than in
boys and during this period of pubertal maturation, a sexual dimorphism is established. The
pubertal growth spurt lasts roughly 2 years longer in boys than in girls, such that boys are taller,
stronger and exhibit higher peak bone mass than do girls (6).
The most beneficial period for osteoporosis prevention maybe during the rapid growth
phases that occur within the first 20 years of life (7). The attainment of higher peak bone mass
during this period should lead to reduced risk for fracture later in life by increasing peak bone
mass.
In this study we are particularly interested in the different rates of bone formation
occurring before, during and after puberty. Bone is a dynamic organ system that is constantly
being remodeled throughout life. The rate of this remodeling is associated with phases of bone
formation and bone resorption. There are primarily two cell types involved in the active
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remodeling of bone: 1) osteoclasts resorb mineralized bone matrix (resorption), and 2) osteoblasts
make bone matrix and play a role in its mineralization (formation). These two processes are
coupled in such a way that resorption is followed by formation (8). During bone growth, bone
formation exceeds bone resorption and the rate of remodeling is high. As peak bone mass is
attained, the rate of remodeling or bone turnover slows and remains low throughout adulthood.
The exception to this rule exists in women where bone resorption increases for 8-10 years
following menopause, but without increased formation, leading to a net loss in bone (9, 10).
In studies comparing bone mass accumulation, Slemenda et al. found that higher peak
bone mass in African American girls is associated with lower bone turnover during puberty
compared to that of Caucasian girls (11). During puberty, a complex series of events occurs that
impacts the changes in bone turnover and attainment of peak bone mass, such as periosteal
expansion and endosteal contraction, longitudinal growth, modeling dependent remodeling (12),
and sex hormone dependent reduction in bone turnover or remodeling (13). With the
development of assays for serum/urine levels of bone formation and resorption markers, the
measurement of bone turnover in different conditions of growth or disease becomes possible.
During growth and in osteolytic diseases, a high bone turnover rate exists (14-17).
Studies using mice as a model system have shown that mice, like humans, attain a peak
bone density (at 4-6 months of age). Some strains experience age related bone loss (1 year and
older) leading to osteopenia (18, 19). Different strains of inbred mice have been shown to exhibit
different peak bone densities (20) and responded differently to ovariectomy (21). Similar to
human studies using monozygotic and dizygotic twins, different strains of inbred mice provide
genetically identical animals to dissect out the role of individual genes and their products in the
development of a trait or disease. However, unlike the design restraints on sample size and
genetic diversity in humans, mice provide a relatively unlimited number of genetically identical
subjects. Two inbred strains of mice, C3H/HeJ (C3H) and C57BL/6J (B6), which have the same
body size and weight and the same bone size, have previously been shown to have very different
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peak bone densities (20, 22-24). Therefore, we chose to compare these two strains to study 1) the
relative contribution of postnatal (from birth until puberty), pubertal and postpubertal growth to
the final peak bone density of each strain, 2) the differences in bone formation and/or resorption
between these two strains that may contribute to these different bone densities, 3) the relationship
between changes in skeletal parameters and biochemical markers of bone turnover between these
two strains during postnatal, pubertal and postpubertal growth, and 4) to determine if and when
the sexual dimorphism in bone density seen in humans after puberty, is also seen in these mice.
C. Materials and Methods
RhIGF-I was a gift from Ciba-Geigy (Basel, Switzerland); rhIGF-II was purchased from
BaChem Chemicals (Torrance, CA). Rabbit polyclonal antiserum against IGF-I (kindly provided
by L.E. Underwood and J.J Van Wyk) was obtained form the National Ftormone and Pituitary
Program (Baltimore, MD). Osteocalcin synthetic peptide was obtained from SynPep Corporation
(Dublin, CA). Paranitrophenol phosphate was purchased from Fluka (Buchs, Switzerland). All
other chemicals were enzyme grade and purchased from Fisher Scientific (Tustin, CA) or Sigma
Chemical Co. (St. Louis, MO).
1. In Vivo Work
Animals - inbred C3H/HeJ (C3H) and C57BL/6J (B6) breeder mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). Upon receipt, the mice were allowed to acclimate to the
new environment for 7 days and were then mated to produce the pups used in this study.
Animal protocol - The female breeders were housed individually several days before expected
parturition and fed a breeders’ diet (10% fat content, Harlan Teklad, Placentia, CA). The pups
were weaned and weighed on postnatal day 21 using a digital scale (ACCULAB V-600) to the
nearest 0.1-gram. At weaning, the pups were fed regular rodent chow (4% fat content, Harlan)
and housed 4-5 pups per cage with cages of females alternating with cages of males on each rack
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to eliminate uneven pheromone distribution. Pubertal maturation in B6 female mice begins when
serum estradiol increases on day 26 and vaginal opening occurs by day 31 (25). In humans,
puberty starts roughly two years later in males than in females, and ends later in males than
females (26). We calculated that in mice, this difference would constitute a 2-3 day delay for
males compared to females, so that puberty should be completed by day 35 in males. Based on
this data, we chose to collect pups at day 7, 14 and 23 (before puberty starts), day 31 (at the end
of puberty for the females), day 35 (at the end of puberty for the males), and on days 42, 49 and
56. Pups were euthanized by C02 inhalation (dry ice) followed by decapitation. Whole blood
was collected, allowed to clot, and then centrifuged. The serum was skimmed off and stored at 70°C until assayed. The left femur was dissected free of soft tissue keeping the condyles and
femoral neck intact. This bone was used for the bone extract assay to determine bone specific
alkaline phosphatase activity (ALP) and bone size data. The right femur and proximal tibia were
dissected free and stored in 70% ethanol for volumetric bone density and geometric parameter
determination using an XCT Research M instrument (Norland Medical Systems Incorporated,
Fort Atkinson, WI). The experimental procedures performed in this study are in compliance with
the NIK guide for the Care and Use of Laboratory Animals. All animals studies were reviewed
and monitored by the Animal Studies Subcommittee at the Jerry L. Pettis Veterans
Administration Medical Center (Loma Linda, CA).
2. Bone Densitometry
Volumetric bone density and geometric parameters were determined by peripheral
quantitative computed tomography (pQCT). pQCT has previously been validated as a reliable
method of determining volumetric bone density and geometric parameters in mice (20). Routine
calibration was performed daily with a defined standard (cone phantom) containing
hydroxyapatite embedded in lucite (Norland Medical Systems). The voxel size was set at 0.07
mm and a half-millimeter thick slice was scanned at the mid-diaphysis. Analysis of the scans was
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performed using the manufacturer-supplied software program (STRATEC MEDIZINTECHNIK
GMBH Bone Density Software, version 5.40C). Volumetric bone density along with geometric
parameters were estimated with Loop analysis. For cortical analysis the threshold was set at 350
mg/cm3 for the 23-56 day old mice in the. 7 and 14 day old mice had lower bone densities than
did the 23-56 day old mice and could not be measured at the 350 mg/cm3 threshold. Therefore
we used a threshold of 150 mg/cm3 for the 7-23 day old mice in the cortical analysis. For
cancellous analysis the outer threshold was set at 250 mg/cm3 and the inner threshold at 300
mg/cm3 for 23-56 day old mice, and 125 mg/cm3 and 150 mg/cm3 for 7-14 day-old mice,
respectively. Values for 7 and 14 day old mice maybe less accurate than for the older mice
because of the lower threshold used, but we have included them in the paper because they show
the rapid growth that occurs during the postnatal period (day 7-23).
3. Biochemical Assays
Femoral bone extraction: the freshly dissected left femora were rinsed in IX PBS for 24 hours at
4°C and then transferred to 0.01% Triton XI00 for 72 hours at 4°C to extract the membrane
bound ALP from the osteoblast cell surfaces. Bone specific ALP activity and total protein
content was determined for this extract. The femora were dehydrated in 75% ethanol and then
allowed to dry out completely at 37°C. Once dry, the femoral length was measured to the nearest
0.01mm using a caliper (Dial Caliper, Mitutoyo Corporation, Japan) and the bones were weighed
to the nearest 0.01 mg using a balance (Millibalance Model 7500, Electrobalance DTE, CAHN
Instruments Inc., Cerritos, CA).
Alkaline Phosphatase Assay of Bone Extracts: ALP activity of the bone extract was determined
using a paranitrophenol phosphate substrate as described previously (27).
Protein Assay: The total protein content of the bone extract was determined using Bradford assay
(BioRad, Hercules, CA).
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Osteocalcin Assay: Osteocalcin levels in serum were measured by specific radioimmunoassay
(RIA) that was previously validated for mouse The mouse osteocalcin RIA had a coefficient of
variation of less than 8% (28).
Separation of IGFBPs from IGFs: Because IGFBPs produce artifacts in IGF RIAs, complete
separation of the IGFBPs from the IGFs is necessary in order for the IGF determinations to be
valid (29).
IGF-I RIA - IGF-I was measured by specific RIA as previously described (30). The cross
reactivity of IGF-II in the IGF-I RIA was less than 0.5%. The sensitivity of the IGF-I RIA was
less than 50 ng/L; the intra- and inter-assay coefficients of variation were less than 10%.
IGF-II RIA - IGF-II was measured by specific RIA as previously described (30). The cross
reactivity of IGF-I in the IGF-II RIA was less than 2%. The sensitivity of the IGF-II RIA was 0.1
pg/L; the intra- and inter-assay coefficients of variation were less than 10%.

4. Statistics
Results are reported as mean ± SD for 7-9 animals per group and compared by two-tailed
three-way ANOVA and Newman-Keuls post hoc test using commercially available statistical
software (STATISTICA, StatSoft Inc., Tulsa, OK). Results were considered significantly
different for P<0.05.

D. Results
The pattern of growth in body weight and femur weight, size and mineral density have
been determined for C3H and B6 mice for the postnatal, pubertal and postpubertal growth
periods. While the general pattern of growth was similar for the two strains of mice, there were
differences in femur bone growth. These differences were statistically significant as determined
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by three-way ANOVA (strain, sex and day). The results of further analysis with Newman-Keuls
post hoc testing is given in the tables and the figure legends.
1. Physical Measurements

a) Body Weight
Weight gain in all the mice was increased roughly three-fold over day 7 during postnatal
growth (day 7-23); and weight gain in B6 mice was identical to that in C3H mice throughout the
study. Within each strain, males gained more weight than females during pubertal growth (in B6,
161% for males and 133% for females; in C3H, 158% for males and 143% for females). After
puberty the weight gain was not different between the sexes (see Tables 1& 2).
b) Femoral Bone Weight
The fastest rate of femoral growth was during the postnatal period (day 7-23) when dry
femoral weight increased eight-fold in B6, and seven-fold in C3H mice. The C3H bones were
slightly but significantly heavier than the B6 bones throughout the study. Male femora were
significantly heavier than female femora by day 56 in B6 and by day 42 in C3H mice (see Tables
1 &2).
c) Femoral Bone Length
Femoral bone length increased two-fold in both strains of mice. Although femora of B6
mice were shorter on day 7, the length increased more than in C3FI mice during postnatal growth
(day 7-23) so that there was no difference between strains from day 23 (see Tables 1 & 2).
Within strains, male femoral length was not different from that of females.

92

2.

Geometric Parameters

a) Area
Total area at the middiaphysis of the femur increased two-fold during postnatal growth
(day 7-23) in both B6 and C3H mice. There was no difference by strain or sex in total area from
day 7-23. Total area in B6 male mice was 9% (P=0.028) greater than that of C3H males on day
49 and 17% (PO.OOl) greater on day 56. B6 female mice had 13% (P=0.008) greater total area
than did C3H females from day 23 onwards (see Tables 1 & 2). The total area at the
middiaphysis in B6 males was 10% (P=0.005) greater than that of B6 females on day 56 and the
value for C3H males was 18% (PO.OOl) greater than that of C3H females by day 42.
b) Cortical Area
Cortical area at the middiaphysis of the femur was not different by strain or sex during
rapid postnatal growth (day 7-23) but cortical area increased by 82% in B6 mice and 63% in C3H
mice (see Tables 1 & 2). By day 31 cortical area was 19% (PO.05) greater in C3H mice than in
B6 mice, this difference was maintained throughout the study. C3H males had greater cortical
area than did B6 male mice on day 31 (17%, PO.02) through day 56 (13%, P=0.005). C3H
females had greater cortical area than that of B6 female mice on day 31 (20%, P0.007) through
day 56 (15%, P=0.01). Within strains, cortical area was 14% (P=0.03) greater in B6 males than
in B6 females by day 56, while cortical area was 19% (PO.OOl) greater in C3H males than in
C3H females by day 42.

c) Medullary Area
Medullary area at the middiaphysis of the femur was significantly greater in B6 mice than
in C3H mice from day 14 (45% in B6 males versus C3H males (PO.OOl), 55% in B6 males
versus C3H males (PO.OOl)) and it increased dramatically during rapid postnatal growth (day 723) in both strains of mice (see Tables 1 & 2). B6 mice had greater medullary area than did C3H
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Table 1: Age changes in measured parameters for male C3H/HeJ and C57BL/6J mice.
days
7
14
23
31
35
Physical parameters
body weight (g)
C3H 3.510.38
18.3l2.4b
18.5±2.6b
6.311.1
11.611.0
B6
17.511.lb
18.2±0.9b
7.110.5
2.810.39
10.910.6
femur weight (mg)
C3H 2.210.32
6.411.4
15.911.8
26.713.0
29.0±3.9
B6
1.810.25
6.210.7
23.612.4
14.510.5
26.6±1.8
femur length (cm)
C3H 0.4710.03b
0.810.06
1.0810.03
1.2510.04
1.28±0.05
B6
0.39l0.03b
0.7610.03
1.0510.02
1.210.04
1.2710.03
Middiaphysis parameters
total area (mm2)
C3H 0.6110.07
1.0810.17
1.3210.1
1.5910.15
1.6510.12
B6
0.5810.06
1.1510.11
1.7510.07
1.4510.06
1.7910.12
cortical area (mm2)
C3H 0.4410.06
0.7210.1
0.7210.08
0.9910. lla
1.04i0.12a
B6
0.3510.04
0.85i0.05ab
0.6710.1
0.6310.04
0.89i0.06a
medullary area
C3H 0.110.03a
0.2510.05a
0.38i0.03a
0.35i0.05a
0.36i0.05a
(mm2)
B6
0.16i0.04a
0.3710.043
0.58i0.03a
0.63i0.04a
0.64l0.06a
endosteal
C3H 1.4i0.15a
2.1310.23
2.74i0.08a
2.7410.12a
2.7610. la
circumference
B6
1.7210.13
2.4610.1 la
3.2110.06a
3.36i0.08a
3.3710.14a
(mm)
C3H 0.210.023
cortical thickness
0.2510.023
0.2110.02a
0.2710.02a
0.2810.03a
(mm)
B6
0.2110.01ab
0.1610.013
0.2110.03a
o.nio.or
0.2210.01a
total density
C3H 224.6137.1
274.6130.23
421127.6a
572.8141.8a
589.4160.7a
(mg/cm3)
B6
159.818.4
213134.8a
244111.8a
351.3122. la
384.2127.23
Serum parameters
IGF-I (ng/ml)
C3H 193125.43
293130.1
293.3170.4
246.7170.6
324.3193.4
B6
81.4l22.6a
232153.5
226.3136
279.3151.9
248.3150.4
osteocalcin (ng/ml)
C3H 181125.4a
329.5l64ab
403156.6a
322151.13
263135.3a
B6
321.1143.5
422190.3 ab
496.3178.8a
471.71713
369.8141.23

42

49

56

21.6l2.0ab
19.211.2 ab
36.412.6b
31.712.3
1.3610.03
1.3210.04

21.912.1 ab
20.412. lab
38.713.7b
34.513.7
1.3810.05
1.3710.05

21.111.4 ab
22.811.0 ab
40.4l4.4b
39.412.lb
1.4310.03
1.4210.04

1.7710.1 lb
1.910.11
1.1810.07 ab
0.9710.04a
0.3310.033
0.64l0.05a
2.7310.12a
3.4210.143

1.8210.13 ab
1.9910.173
1.25l0.14ab
1.0510.13
0.3110.03a
0.66i0.06a
2.69i0.07a
3.4510.14a

1.810.16 ab
2.1110.11 ab
1.2610.13 ab
1.1110.05 ab
0.2810.053
0.7l0.06a
2.5910.23
3.5410.14a

0.3210.01 ab
0.2310.01
680.5112.la
416.3117.6a

0.3310.03 ab
0.2510.01 ab
715.4166.5a
442.2111.4a

0.3410.03 ab
0.2610.01a
758.1148.5a
474.4114.2a

390165
288156.2
274145.7a
365.6162.1

392173.2
258.3173.7
221.9127
287.1143.7

337.7183
336.4151.7
180.6142.4
229.9145.3

Values presented as mean 1 SD for 7-9 animals. a=P<0.05 versus opposite strain males and b=P<0.05 versus same strain females.

Table 2: Age changes in measured parameters for female C3H/HeJ and C57BL/6J mice.
days
7
14
23
31
35
42
49
56
Physical parameters
body weight (g)
C3H 3.2+0.52
15.1±1.2b
15.9±0.6b
17.7+1.2b
18.9+1.2b
6.8+1.2
10.5+1.7
17.0+1.4b
B6
14.0+1.4b
15.6±1.4b
14.5±2.6b
17.6+0.8b
18.6+1.0b
10.5+0.4
2.7+0.24
6.4+0.8
femur weight (mg)
C3H 2.1+0.51
37.5+3,2b
31.9±4.4b
15.3+3.0
6.8+1.5
23.8+3.9
29.4+3.2
27.2±1.7
B6
33.9±3.8b
14.6+0.7
1.7+0.23
5.6+0.8
22.5+1.9
24.6+2.5
26.9+3.0
31.2+1.8
femur length (cm)
C3H 0.44+0.03b
0.8+0.06
1.08+0.05
1.2+0.07
1.26+0.02
1.29+0.04
1.33+0.04
1.39+0.03
B6
0.4±0.02b
1.05+0.2
0.74+0.03
1.23+0.03
1.34+0.04
1.19+0.05
1.27+0.05
1.37+0.03
Middiaphysis parameters
total area (mm2)
C3H 0.56+0.11
1.56+0.1 lab
1.05+0.13
1.24+0.1 la
1.48+0.143
1.53+0.073
1.56+0.05 ab
1.69+0.18 ab
B6
0.5+0.14
1.07+0.08
1.24+0.1 la
1.48+0.143
1.53±0.07a
1.5+0.053
1.56±0.11a
1.69+0.18 ab
cortical area (mm2) C3H 0.41+0.01
1.04±0.1b
1.13+0.1 lab
0.71+0.1
0.66+0.08
0.89+0.1
0.95+0.08
0.99+0.06 ab
ab
B6
0.98±0.07b
0.32+0.1
0.59+0.06
0.58+0.04
0.86+0.09
0.74+0.05
0.85+0.05
0.92+0.063
medullary area
C3H 0.09+0.04
0.23+0.033
0.38+0.053
0.35+0.023
0.35±0.04a
0.28+0.043
0.27+0.03a
0.32+0.16a
(mm2)
B6
0.36+0.043
0.1+0.08
0.61+0.053
0.61±0.06a
0.62+0.053
0.64+0.063
0.67+0.06a
0.66+0.06a
endosteal
C3H 1.41+0.na
2.07+0.12a
2.69+0.12a
2.72+0.12a
2.69±0.07a
2.52+0.1 la
2.54+0.083
2.64+0.36a
circumference
B6
2.43+0. IT
1.49+0.193
3.23+0.lla
3.34+0.15a
3.31+0.123
3.32+0.1 la
3.43+0.13a
3.46+0.133
(mm)
Cortical thickness
C3H 0.2+0.033
0.25+0.02a
0.29±0.02ab
0.2+0.023
0.25+0.023
0.27+0.023
0.3+0.02 ab
0.31+0.03 ab
(mm)
B6
0.19±0.01ab
0.22+0.0 lab
0.16+0.033
0.2+0.023
0.16+0.013
0.22+0.023
0.23+0.01
0.21+0.013
total density
C3H 207.3+27.3a
307+35.8a
390.7+34.8a
535.5+34.3a
575.4+48.la
652.1+51.la
688+53.la
710.6+1093
(mg/cm3)
B6
163.5+12.43
162.2+36.7a
227.4+33. la
306.5+23.43
397.7+25.3a
362.9+29.8a
366.5+20. la
439.5+20.73
Serum parameters
IGF-I (ng/ml)
C3H 182±51.2a
305+41.3a
282.2+83.3
277.7+63.3
295.7+82.9
338.7+83.1
288+79
265.3+46.5
B6
87.3±43.2a
176.3+43.3a
260.3+81.9
252+69.5
296.7+40.4
213+45.8
177+112.5
274+42.6
osteocalcin (ng/ml) C3H 178+46.5a
436+156.5 ab
230.3+42.4
280+33.6a
282.4+35.7
251.4+50.8
206.3+32.6
272.3+12.5
B6
345.7±49.2a
554.9+154 ab
400.6+56.2
519.3±49a
304.6+98.8
280.4+39.5
270.1+33.1
276.3+38.1
Values presented as mean ± SD for 7-9 animals. a=P<0.05 versus opposite strain females and b=P<0.05 versus same strain males.mice for the duration of the
study, 55% (PO.OOl) at day 23, 78% (PO.OOl) at day 35 and 128% (PO.OOl) at day 56. Within strain there was no difference between sexes at any time
during the study.

d) Periosteal Circumference
Periosteal circumference at the middiaphysis of the femur did not differ across strain or
sex during rapid postnatal growth (day 7-14) (see Figure 1). B6 females had 7% (P<0.05) greater
periosteal circumference than that of C3H females from day 23, and B6 male mice had 8%
(P<0.001) greater periosteal circumference than that of C3H males at day 56. Within strains,
periosteal circumference in B6 males was 5% (P=0.01) greater than that of B6 females by day 56
and periosteal circumference was 8% (P<0.001) greater in C3H males than that of C3H females
by day 42.
e) Endosteal Circumference
Endosteal circumference of the middiaphysis increased 65-90% during rapid postnatal
growth (day 7-23) and a total of 7-10% during pubertal (day 23-31) and postpubertal growth (day
31-56) in B6 mice. In C3H mice, endosteal circumference increased by 60-70% during rapid
postnatal growth (day 7-23) but did not change throughout the rest of the study. Endosteal
circumference was significantly greater in B6 mice than in C3H mice for the entire study. Within
strains, endosteal circumference did not differ across sex for the entire study (see Tables 1 & 2).
f)

Cortical Thickness

Cortical thickness at the middiaphysis of the femur was roughly 30 % (P<0.01) greater in
C3H mice than in B6 mice throughout the study. Within strains, cortical thickness was 9%
(P<0.05) greater in C3H males than in C3H females from day 42. But no differences across sex
were evident in B6 mice (see Tables 1 & 2). The greatest increase in cortical thickness occurred
during rapid postnatal (day 7-23) and pubertal (day 23-31) growth, while the rate of change in
cortical thickness decreased dramatically after puberty.
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3. Bone Densitometry

a) Mineral Content
Total mineral content of the femoral middiaphysis increased four-fold in both B6 mice
and C3H mice during rapid postnatal growth (day 7-23) (see Figure 2). Total mineral content in
C3H mice was roughly 40% (P<0.01) greater than that of B6 mice throughout the study (44% on
day 7, 54% on day 31, and 38% on day 56). Within strain, total mineral content of B6 males was
23% (P=0.04) greater than that of B6 females by day 31, and 23% (P<0.001) greater in C3H
males than in C3H females on day 42.
b) Density
Total volumetric bone density of the middiaphysis increased more in C3H mice (females 81%
and males 83%) than in B6 mice (females 37%, males 51%) during rapid postnatal growth (day
7-23). Greater volumetric bone density was present in C3H mice on day 7 (C3H vs. B6 females
27%, and C3H vs. B6 males 41%, PO.05), and by day 56 this difference was even greater (C3H
vs. B6 females 60%, and C3H vs. B6 males 62%, P<0.001). Within strain, there was no
difference in volumetric bone density between sexes (see Tables 1 & 2 and Figure 3). The
greatest difference in rate of total density accretion occurred during rapid postnatal (day 7-23) and
pubertal (day 23-31) growth (see Figure 4). The rate of bone density gain in C3F[ mice during
postnatal and pubertal growth was twice that of B6 mice, while it was not different after puberty.
4. Biochemical Assays

a) Serum IGF-I
C3H mice had significantly higher serum levels of IGF-I than did B6 mice on day 7 and
14 (see Tables 1 & 2).
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b) Serum IGF-II
On day 7 and 14 IGF-II levels were not different by strain or sex. By day 23, serum IGFII was nearly undetectable and remained at low levels for the duration of the study (data not
shown).
c) Serum Osteocalcin
Serum osteocalcin was significantly higher in B6 mice compared to that of C3H mice
from day 7 (77%, P<0.01) to day 42 (33%, P<0.01) in males; and from day 7 (94%, P<0.01) to
day 23 (7%, P<0.01) in females. Serum osteocalcin increased roughly two-fold during postnatal
growth (day 7-23) in male mice of both strains, and then decreased steadily until day 56.
However, in female mice, serum osteocalcin levels doubled from day 7-14 and then decreased
steadily until day 56 (see Tables 1 & 2). Serum osteocalcin levels in female mice of both strains
were 32% higher than in male mice on day 14 (P<0.01), but were not different at other time
points.
d) Bone Extract ALP
Bone extract ALP normalized for total extractable protein showed a four fold increase in
activity during the rapid-bone modeling associated with increased bone length and size during
postnatal growth (day 7-23) in both strains, although bone extract from C3H mice contained two
fold greater ALP activity on day 14 than that of B6 mice. A decrease of 30% in ALP activity
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Figure 1: Changes in periosteal circumference in C3H/HeJ (C3H) and C57BL/6J (B6) mice from
day 7 through day 56. At day 23 periosteal circumference was 5% (P=0.03) greater in B6 males
and 7% (P<0.01) B6 females than in C3H males and females, respectively. On day 56, periosteal
circumference was 9% (P<0.001) greater in B6 males and 7% (P<0.01) greater in B6 females
than in C3H males and females, respectively. Within strain, B6 males had 5% (P=0.01) greater
periosteal circumference than B6 females on day 56 and C3H males had 8% (PO.OOl) greater
periosteal circumference than C3H females on day 42. Values expressed as mean of 7-9 animals
± SD; B6 males = closed triangle, B6 females = closed circles, C3H males = open triangles, C3H
females = open circles; SD = bars.
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Figure 2: Changes in middiaphysial total mineral content in C3H/HeJ (C3H) and C57BL/6J (B6)
mice from day 7 through day 56. On day 23, C3H males had 56% (P<0.001) and C3H females
had 51% (P<0.01) greater total mineral content than B6 males and females, respectively. On day
35, C3H males had 42% (PO.OOl) and C3H females had 39% (PO.OOl) greater total mineral
content than B6 males and females, respectively. On day 56, C3H males had 36% (PO.OOl) and
C3H females had 40% (PO.OOl) greater total mineral content than B6 males and females,
respectively. Within strain, B6 males had 23% (P=0.04) greater mineral content than B6 females
by day 31 and C3H males had 23% greater mineral content (PO.OOl) than C3H females on day
42. Values expressed as mean of 7-9 animals ± SD; B6 males = closed triangle, B6 females =
closed circles, C3H males = open triangles, C3H females = open circles; SD = bars.
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Figure 3: Changes in bone density in C3H/HeJ (C3H) and C57BL/6J (B6) mice from day 7
through day 56. Total volumetric bone density of the middiaphysis was about 30% greater in
C3H mice than in B6 mice at day 7. C3H mice exhibited 70% more bone density than did B6
mice after puberty (day 31). Bone density more than doubled during puberty in both strains of
mice. Values expressed as mean of 7-9 animals ± SD; B6 mice = closed triangle, C3H mice =
open triangles; SD = bars.
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Figure 4: Changes in the rate of volumetric bone density accretion per day in C3H/HeJ (C3H) and
C57BL/6J (B6) mice from day 7 through day 56. C3H mice had a 2.8-fold -and a 1.6-fold higher
rate of bone accretion from day 7-14 and day 23-31 respectively, compared to B6 mice. The gain
in bone density for each time period was calculated from the mean value for each time period and
was divided by the duration in days to obtain the rate. Males and females were calculated
separately and used as replicate values for the calculation of significance. B6 mice = closed
triangles, C3H = open triangles.
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Figure 5: Changes in bone specific ALP activity in bone extracts for C3H/HeJ (C3H) and
C57BL/6J (B6) mice from day 7 through day 56. On day 14 bone specific ALP activity in C3H
males was 75% (PO.OOl) and C3H females was 95% (P<0.001) greater than B6 males and
females, respectively. On day 23, C3H males had 21% (P<0.01) greater bone specific ALP
activity than B6 males, but C3H females were not different to B6 females. Values expressed as
mean of 7-9 animals ± SD; B6 males = closed triangle, B6 females = closed circles, C3H males =
open triangles, C3H females = open circles; SD = bars.
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occurred during puberty (day 23-31). Higher ALP activity was present in bone extract from C3H
male mice during postnatal growth than that of B6 males, but there was no difference between
C3H and B6 females (see Figure 5). Within strains there was no difference in ALP activity
between sexes at any time.
5.

Correlations

In both strains, body weight was highly correlated with all other physical, geometric and
densitometry measurements throughout the study (see Table 3 & 4).
Serum osteocalcin showed a negative correlation with physical, geometric and densitometry
measurements in both strains. In B6 male and females, serum osteocalcin was negatively
correlated with the other parameters; however, in C3H mice, this correlation was weak or not
significant (see Table 3 & 4). During postnatal growth serum osteocalcin showed a positive
correlation with these parameters in both strains but more so in the males (see Table 5).
A positive correlation between bone extract ALP activity and physical, geometric and
densitometric measurements in both B6 and C3H mice was present (see Table 3 & 4). Although,
during the decrease in ALP activity that occurred during puberty, this correlation was highly
negative in both sexes of both strains (see Table 5).
Serum IGF-I levels were positively correlated with physical, geometric and densitometry
measurements in both strains (see Tables 3 & 4), especially during postnatal growth but less so
during pubertal and postpubertal growth (see Table 5).
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Table 3: Correlation of physical, geometric and densitometry measurements in C3H/HeJ mice.
WT
IGF-I Osc
ALP
area
bone wt
bone l
mineral
density
thickness
TT
WT
Too
TT
TT
TT
11
.12
sf
^9T
.55*
.55*
.57*
.53*
IGF-I
1.00
.11
.09
.60*
.58*
.48*
-.23*
-.20*
-.20*
Osc
1.00
-.04
-.21*
-.00
ALP
.28*
1.00
.05
.26*
.07
13
.05
bone wt
1.00
.94*
.94*
.97*
.99*
.85*
.75*
Bone 1
.93*
.93*
.96*
1.00
Mineral
.94*
.98*
.90*
1.00
Density
.90*
.88*
1.00
Area
.81*
1.00
thickness
1.00
Peri c
Endo c

peri c

endo c
J9"

.60*

.46*
.22*
.54*
.73*

.05

.31*
.92*
.97*
.92*
.89*
1.00*
.79*
1.00

.88*
.70*

.67*
.88*
.44*

.90*
1.00

WT = body weight, IGF-I = serum IGF-I levels, Osc = serum osteocalcin levels, ALP = bone extract alkaline phosphatase activity, bone wt =
femoral dry bone weight, bone 1 = femoral dry bone length, mineral = total mineral content, density = volumetric bone density, area = total bone
area. Thickness = cortical thickness, peri c = periosteal circumference, endo c = endosteal circumference. *=P<0.05.
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Table 4: Correlation of physical, geometric and densitometry measurements in C57BL/6J mice.
WT
IGF-I
ALP
Osc
bone wt
bone l
mineral
density
area
thickness peri c
endo c
WT
loo
W
7W 738"
AT
797"
^96"
^94"
JT
.55*
.52*
.45*
IGF-I
.41*
.62*
1.00
-.00
.61*
.66*
.61*
.59*
-.55*
-.57*
-.40*
-.35*
Osc
.28*
-.48*
1.00
-.46*
-.31*
-.26*
.33*
.20*
.37*
.52*
.20*
.42*
ALP
1.00
11
.56*
.73*
bone wt
1.00
.95*
.98*
.96*
.95*
.92*
.85*
Bone 1
.91*
.90*
.97*
.65*
.97*
1.00
.96*
Mineral
.98*
.94*
.83*
1.00
.81*
.91*
.77*
Density
.91*
.82*
1.00
.88*
.74*
Area
1.00
.99*
.95*
.72*
.52*
thickness
1.00
Peri c
.97*
1.00
Endo c
1.00
WT = body weight, IGF-I = serum IGF-I levels, Osc = serum osteocalcin levels, ALP = bone extract alkaline phosphatase activity, bone wt =
femoral dry bone weight, bone 1 = femoral dry bone length, mineral = total mineral content, density = volumetric bone density, area = total bone
area. Thickness = cortical thickness, peri c = periosteal circumference, endo c = endosteal circumference. *=:P<0.05.

o

Table 5: Correlation of serum IGF-I, osteocalcin and bone extract ALP to other parameters during postnatal, pubertal and postpubertal
growth.
Postpubertal
Pubertal
Postnatal
ALP
Osc
IGF-I
ALP
IGF-I
Osc
IGF-I
ALP
Osc
B6
C3
C3
B6
C3
B6
C3
B6
B6
C3
B6
C3
B6
C3
B6
C3
B6
C3
-.06 -.02
-.15 -.05
74*” -.22
-.14 758* 757 ~aT
WT
J8* 7T" 3T 7(7 ^90* OT ~25
-.07
.20
.22
-.37* 1.00
1.00 .03
.49*
-.05
.15
.60*
.28* 1.00 1.00
.57*
IGF-I
1.00 1.00 .39*
.28
.18
1.00 1.00
.36* .03
.22
1.00 1.00 .61*
.49* .49*
-.05
1.00 1.00 .44*
.39*
.57*
Osc
1.00 1.00
.28
.20
.18
.36*
1.00 1.00 -.07
-.37* .61*
.44*
.49*
1.00 1.00 .15
.60*
.28*
ALP
-.01
-.21
-.38* -.21
.36*
-.47* -.30* -.74* -.67* .54*
.95*
.82* .06
.39*
.70*
.47*
.47*
.50*
bone wt
-.20 -.46* -.14
.03
.35*
-.54* -.29* -.74* -.66* .54*
.38*
.56*
.60*
.89*
.88* .00
.77*
.57*
Bone 1
-.25
-.39* -.04 -.16
.33*
.36*
-.42*
19 -.64* -.60* .50*
.86*
.82* .03
.72*
.52*
.32*
.59*
Mineral
-.23
-.41* .05
15
-.62* -.62* .42*
.14
.32*
-.43* -.21
.14
.55*
.72*
.82* -.01
.65*
.46*
Density
-.14
-.11
.50*
.40*
-.20
-.24
-.62*
-.57*
-.37* -.13
.82*
.82* .05
.37*
.73*
.64*
.44*
.65*
Area
-.24 -.39* .04
-.17
.27
-.63* -.60* .41*
-.01
.36*
-.40* -.14
.58*
.10
.45*
-.25
.05
thickness .23
-.14
-.11
.51*
.40*
-.19
-.23
-.63*
-.57*
.04
.37*
-.37*
-.12
.79*
.82*
.73*
.65*
.45*
.66*
Peri c
-.25
.04
-.39* -.12 .45* .22
-.09 .10
.89*
.87* .10
-.20
.01
.69*
.51*
.44*
.58*
.15
Endo c
WT = body weight, IGF-I = serum IGF-I levels, Osc = serum osteocalcin levels, ALP = bone extract alkaline phosphatase activity, bone wt =
femoral dry bone weight, bone 1 = femoral dry bone length, mineral = total mineral content, density = volumetric bone density, area = total bone
area. Thickness = cortical thickness, peri c = periosteal circumference, endo c = endosteal circumference. *=P<0.05.

E. Discussion
In previous studies, two inbred strains of mice, C3H and B6, exhibited similar body
weights but different volumetric peak bone densities (20, 22-24). In order to identify the growth
period/s in which this divergence in bone density becomes apparent, we evaluated temporal
skeletal changes in C3H and B6 mice belonging to both sexes before, during and after puberty.
Our data shows that while C3H mice exhibit slightly higher total bone density compared to B6
mice at 7 days of age (approximately 25%), total bone density is 69% greater in C3H mice
compared to B6 mice at 31 days of age, despite similar body size, body weight, and bone length.
Accordingly, the gain in bone density in C3H mice during postnatal (day 7-23) and puberty (day
23-31) growth is more than twice compared to that of B6 mice. In addition, the findings that the
gain in bone density increases by more than 70% during puberty (day 23-31) attest that rapid
skeletal changes occur during this period. Therefore, the postnatal (day 7-23) and pubertal (day
23-31) growth periods appear to be critical in the development of the difference in bone density
between C3H and B6 mice. The difference in total bone density seen at day 35 between C3H and
B6 mice was maintained during the rest of the study period.
The differences in cortical thickness between the two strains of mice reflect the greater
accumulation of bone mineral in C3H mice compared to B6 mice during postnatal growth. This
difference in cortical thickness between C3H and B6 mice developed during the rapid growth of
the postnatal (day 7-23) and pubertal (day 23-31) periods. The difference in cortical thickness
between C3H and B6 mice appeared to be due to significantly smaller endosteal circumference in
C3H mice (approximately 20% less) compared to B6 mice. The increase in cortical thickness of
approximately 25% during puberty (day 23-35) in both strains of mice appeared mainly to be due
to increased periosteal circumference, since the endosteal circumference did not show significant
change during this period. While neither the periosteal nor the endosteal circumference showed
significant change during postpubertal growth (day 35-56) in C3H mice, both the periosteal and
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endosteal circumference increased in B6 mice during this period, resulting in B6 mice having
significantly greater periosteal circumference than C3H mice at 56 days. Consistent with these
data, Sheng et al. (24) have recently shown, by histomorphometric analysis, that the total cross
sectional area of the femur at the middiaphysis is significantly greater in the B6 mice at 6 weeks
of age compared to C3H mice.
The cellular mechanisms that contribute to the greater cortical thickness in C3H mice
compared to B6 mice can only be speculated at this time. In this regard, the findings that
endosteal but not periosteal circumference is significantly different between the two strains of
mice during postnatal growth suggested that differences in endosteal bone formation and
resorption could, in part, contribute to the observed differences in cortical thickness. Consistent
with this idea were the findings that: 1) C3H mice exhibited significantly higher ALP activity in
the femoral bone extract than did B6 mice at the time when maximal differences in bone density
between the two strains occur; 2) C3H mice exhibited greater endosteal bone formation rate than
B6 mice by histomorphometric analysis (24); and 3) there were fewer osteoclast precursors in the
marrow of C3H mice than in B6 mice (31). Further studies are needed to evaluate the relative
contribution of endosteal bone formation versus endosteal bone resorption in contributing to
differences in cortical thickness between the two strains of mice during postnatal growth.
The divergence in total volumetric bone density at the femoral middiaphysis between
C3H and B6 strains during postnatal growth may, in part, be due to greater bone area in the C3H
mice than in the B6 mice due to differences in cortical thickness. However, the possibility that
the bones of C3H mice during early postnatal growth may be more mineralized or less porous
compared to B6 mice cannot be ruled out since C3H mice exhibit approximately 30% greater
bone density than B6 mice despite similar bone area on day 7. Although the finding that C3H
mice exhibit greater ash weight and calcium content compared to the B6 mice at 9 weeks of age
(22) are consistent with this idea. Further studies are needed to evaluate whether or not C3H
bones contain less porosity or more mineralization of the bone matrix compared to B6 mice
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during postnatal growth when the greatest difference in density was seen despite similarities in
bone area.
The rapid increase in total mineral content during postnatal growth (day 7-23) appeared
to be mainly due to increased bone size which increased by more than 50% during this period
(see Figure 6). This increase in bone size appeared to be caused by increased periosteal bone
formation rate since both osteocalcin levels in the serum and ALP activity in bone extract
increased during this period. In terms of the individual factors that contribute to the increased
periosteal bone formation, we postulate that IGF-I maybe a potential candidate since 1) serum
levels of IGF-I increased dramatically during this period (see Tables 1 & 2) and showed
significant correlation with changes in periosteal circumference and biochemical measurements
of bone formation during this period (see Table 5), and 2) mice lacking IGF-I exhibit dramatic
reduction in postnatal skeletal growth (32). Consistent with a role for IGF-I, our findings also
demonstrate significantly greater serum IGF-I levels in C3H mice than in B6 mice on days 7 and
14. Although the higher levels of IGF-I in the C3H where not statistically significant at later time
points in this study, we have previously shown that the IGF-I differences are statistically
significant up to 10 months of age (23). Further studies are needed to evaluate the cause and
effect relationship between changes in serum levels of IGF-I and skeletal changes in C3H and B6
mice during postnatal growth.
In contrast to postnatal growth, the mineral accumulation during puberty appears to be
predominantly due to decreased bone resorption caused by increased male and female sex steroid
hormones. There are a number of findings that support this idea. First, the increase in total bone
density during puberty in both C3H and B6 mice showed significant negative correlation with
biochemical markers of bone turnover in both serum and bone extracts (see Tables 3 & 4).
Second, we and others have shown that the increase in mineral accumulation during sexual
development in girls is associated with decreased bone turnover (11, 13, 33). Third, Slemenda et
al. (11) have shown that African American children accumulated 10% greater bone mass and had
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Figure 6: A model of the changes in bone size during postnatal, pubertal and postpubertal growth in C3H/HeJ (C3H) and C57BL/6J (B6)
mice. On day 7, the periosteal circumference of C3H and B6 femora was similar, as illustrated by the cross-sectional diagram of the femur
at the middiaphysis, B6 had a 20% great endosteal circumference than did C3H, and C3FI had 34% greater volumetric bone density than did
B6 mice. Between day 7 and 23 periosteal circumference increased 50% in C3H mice and 58% in B6 mice, while endosteal circumference
increased by 90% in both strains. On day 23, the periosteal circumference of C3H and B6 femora was similar, B6 had 16% great endosteal
circumference than did C3H mice, and C3H had 69% greater volumetric bone density than did B6 mice. On day 35 B6 mice had about 4%
greater periosteal circumference than did C3H mice, B6 had a 22% great endosteal circumference than did C3H, and C3H had 56% greater
volumetric bone density than did B6 mice. On day 56, B6 mice had 7-8% greater periosteal circumference than did C3H mice, B6 had a
35% great endosteal circumference than did C3H, and C3H had 61% greater volumetric bone density than did B6 mice.

endosteum

C3
periosteum

B6
endosteum

Days

7

23
►

postnatal

◄ ----------- ►

pubertal

35
◄

postpubertal

56

significantly reduced bone turnover, as measured by serum levels of osteocalcin and tartrate
resistant acid phosphatase, compared to Caucasian children during pubertal growth.Although sex
steroid hormone-induced changes in cytokine production (34-36) have been implicated in the
reduced bone turnover that occurs during puberty, the cause and effect relationship between
cytokine production and the reduction in bone turnover during puberty remains to be established.
Surprisingly, we found that serum osteocalcin levels were significantly lower in C3H
mice compared to B6 mice throughout the study. Because ALP activity in bone extract was
significantly higher in the C3H mice than B6 mice during postnatal growth, we anticipated serum
osteocalcin levels to also be higher during this period in C3H mice. There are a number of
potential explanations for this discrepancy. It is possible that osteocalcin expression in
osteoblasts is higher in C3H mice compared to B6 mice; however, a smaller proportion of
synthesized osteocalcin was released into the extracellular fluid compared to the matrix
compartment in C3H mice compared to B6 mice, resulting in reduced levels in serum. Metabolic
differences in serum osteocalcin (e.g. half-life, clearance rate) between C3H and B6 mice may
also contribute to the lower levels of serum osteocalcin in C3H mice compared to B6 mice.
Alternatively, the higher level of osteocalcin produced in the B6 mice may act as an inhibitor of
bone formation during postnatal growth since bone formation was increased at the endosteum in
mice lacking osteocalcin (37).
Our findings also demonstrate that sexual dimorphic skeletal changes occurred in mice
during puberty as in the case of humans (4). This sexual dimorphism maybe attributed to greater
bone size and cortical thickness in men than in women (38), which in turn maybe due to a later
start and a longer pubertal growth period in boys than girls (5). However, volumetric bone
mineral density does not appear to be different between the two sexes in humans (39-41). Within
strains, we found that 8 week old male mice had a greater total mineral content (see Figure 2) and
a larger periosteal circumference (see Figure 1) than did females, despite similar endosteal
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circumference. Thus, male mice of both strains exhibited increased bone size and cortical
thickness resulting in greater total mineral content compared to female mice (see Figure 7). The
molecular mechanisms that are responsible for the increased periosteal bone formation and/or
reduction in periosteal bone resorption in the males compared to females have yet to be
established.
In conclusion, our findings demonstrate that two growth periods, postnatal and pubertal,
are critical to the development of peak bone mineral density between C3H and B6 strains of mice.
We speculate that the genes that contribute to the difference in bone mineral density during each
of these periods may be different. The genes that are differentially expressed in the skeleton of
C3H and B6 mice during postnatal and pubertal growth may provide clues regarding the genes
that contribute to the differences between these two strains of mice.
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Figure 7: A model of changes in bone size that contribute to the development of sexual dimorphism between male and female mice during
postnatal, pubertal and postpubertal growth. On day 7, male and female femoral periosteal and endosteal circumference are similar, as
illustrated by the cross-sectional diagram of the femur at the middiaphysis. Between day 7 and 23, the femoral periosteal circumference
increases by roughly 50%, and the endosteal circumference by 90% in both male and female mice. On day 23, the femoral periosteal and
endosteal circumferences are still similar. Between day 23 and 56, periosteal circumference increased by 17% in female mice and by 21%
in male mice, but endosteal circumference remained unchanged. On day 56 male mice had 5% greater periosteal circumference than female
mice did but similar endosteal circumference.
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A. Abstract
IGFBP-5 is stored in bone and stimulates osteoblast cell proliferation in vitro. Bone
formation (BF) is dependent on number and activity of osteoblasts. We therefore evaluated the
ability of rhIGFBP-5 to increase osteoblast activity in vitro; both ALP (ALP) activity and
osteocalcin levels showed a dose-dependent increase. In in vivo time course studies, daily
subcutaneous administration of 50 pg rhIGFBP-5 per day per mouse significantly increased
serum osteocalcin levels by day 7 and these levels were sustained through day 21. We further
evaluated if rhIGFBP-5 was as effective as IGF-I. Daily subcutaneous administration of
rhIGFBP-5 (50 ug/day), IGF-I (13 ug/day) or IGF-I+rhIGFBP-5 complex for 9 days increased
serum osteocalcin levels by 58%, 65% and 81% (P<0.001 in all) and femoral bone extract ALP
activity by 85% (PO.OOl), 29% (P<0.05) and 13% (NS) respectively, and decreased
carboxyterminal cross-linked telopeptide of type I collagen by 29% (P<0.05), 20% (NS) and
12.5% (NS) respectively. One subcutaneous injection of IGFBP-5 (50 ug/mouse) increased serum
osteocalcin and bone ALP activity by 21% (P<0.05) and 27% (P<0.02) respectively after 5 days,
but did not significantly increase serum IGF-I (1, 6 or 24 hours/post injection) suggesting that
rhIGFBP-5 effects on bone are not mediated by increasing circulating IGF-I. Our data
demonstrate that systemic administration of rhIGFBP-5 either alone or in combination with IGF-I
increases BF parameters in vivo.
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B. Introduction
The insulin-like growth factor (IGF) system has been shown to modulate growth in many
tissues, such as, nervous tissue, lymphoid tissue, reproductive tissue, smooth muscle, endothelium
and bone (1, 2). A number of in vitro and in vivo findings demonstrate that IGF-I and IGF-II are
important regulators of bone formation. When added exogenously, both increase osteoblast cell
proliferation and differentiation in vitro, and bone formation in vitro and in vivo (2-7). Mice
lacking functional IGF-I and/or IGF-II genes exhibit severe impairment of bone formation (8). In
addition, an adolescent male human with a disrupted IGF-I gene had a bone mineral density
significantly less than that found in other studies of healthy adolescent human males (9).
Both IGF-I and IGF-II are produced by osteoblasts and their mitogenic effects are
mediated by their binding to the IGF plasma membrane receptors. The IGF type 1 receptor, which
binds both IGF-I and II, appears to be the predominate receptor involved in mediating the effects
of these growth factors in most cell types, including osteoblasts (10, 11). Insulin-like Growth
Factor Binding Proteins (IGFBPs) modulate the actions of secreted IGFs by binding to them and
IGFBPs also increase the IGF’s half-life in the extracellular milieu and circulation by
sequestering them in this bound form. The IGFBPs either enhance or inhibit IGF actions on target
cells (12, 13), in bone the individual IGFBPs either inhibit or potentiate IGF effects on
osteoblasts (4, 12-17). Of the various IGFBPs secreted by bone cells, IGFBP-5 has several unique
features that suggest that it is a key component of the IGF system in bone. IGFBP-5 is the most
abundant IGFBP stored in bone, having a high specific binding affinity for hydroxyapatite and
extracellular matrix proteins, therefore fixing it and its bound IGFs within bone (18-20). We have
previously proposed that the local release of these sequestered IGFs and IGFBP-5 in bone could
provide the mechanism whereby osteoclastic bone resorption during remodeling gives rise to a
coupled increase in bone formation. Therefore, the significant age-related decline in skeletal
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content of IGF-I which is positively correlated with decreasing IGFBP-5, could contribute in part
to the age-related impairment in the coupling of bone formation to resorption (18, 19, 21).
IGFBP-5 is also unique in that it is the only IGFBP that has been shown to consistently
stimulate osteoblast cell proliferation in vitro (20, 22-24) thus increasing the number of
osteoblasts. Recent studies suggest that the mitogenic effects of IGFBP-5, may in part be
independent of IGFs and mediated through IGFBP-5’s own signal transduction pathway (14, 25).
Because bone formation is dependent not only on the number but also on the activity of
osteoblasts, in this study we evaluated if rhIGFBP-5 also increases the activity of osteoblasts in
vitro. Based on our findings that rhIGFBP-5 treatment increases osteoblast cell activity (increases
osteocalcin production and alkaline phosphatase activity), we further investigated the effect of
rhIGFBP-5 on bone formation in an intact animal model.
C. Materials and Methods
The human osteosarcoma cell line, MG63 was purchased from ATCC (Rockville,
Maryland). Untransformed normal human bone cells were a kind gift from Dr. John Wergedal
(Loma Linda, CA) (26). Dulbecco’s Modified Eagle’s Medium (DMEM), calf serum (CS), 1,25
dihydroxy vitamin D3, and IGF-I was purchased from Mediatech, Inc. (Herndon, Virginia),
HyClone (Logan, Utah), Biomol (Plymouth Meeting, Pennsylvania), and Gropep (Adelaide,
Australia), respectively. rhIGFBP-5 was expressed in E. coli and purified to homogeneity as
described previously (14), this preparation did not contain detectable levels of IGF-I or IGF-II as
measured by specific RIA. rhIGFBP-5 has been shown to have similar IGF binding and
biological activity to native human IGFBP-5 (14). Bovine Serum Albumin (BSA) and
paranitrophenol phosphate was purchased from Fluka (Buchs, Switzerland). All other chemicals
were enzyme grade and purchased from Fisher Scientific (Tustin, California) or Sigma Chemical
Co. (St. Louis, Missouri). Of the inbred mouse strains used, Balb/c were purchased from B&K
suppliers (Fremont, CA) and C3H/HeJ from Jackson Laboratory (Bar Harbor, Maine).
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1. In Vitro Experiments
Cells were grown at 37°C in humidified incubators with 5% C02. For osteocalcin
experiments, conditioned medium was collected from serum free (DMEM/0.1% BSA) cultures of
MG63 or normal human bone cells treated with various concentrations of rhIGFBP-5 and 10‘8 M
1,25 dihydroxy vitamin D3 (1,25 (OH)2 D3). This conditioned medium was frozen at -70°C until
assayed for osteocalcin by specific RIA (27), the cells were extracted and this extract assayed for
protein concentration (28).
For alkaline phosphatase (ALP) activity experiments, serum free (DMEM/0.1% BSA) cultures of
MG63 or normal human bone cells were treated with various concentrations of rhIGFBP-5 in the
presence or absence of 10“8M 1,25 (OH)2 D3. The cell lysate was assayed for ALP activity (29).
2. In Vivo Experiments
7-week-old Balb/c or C3H/HeJ inbred mice were used for the in vivo experiments. The
animals were housed in a controlled environment with 12-hour light/dark cycles at 70°F with
food and water ad libitum. In each experiment the treatment was injected subcutaneously at the
nape of the neck of each mouse at the same time each day (9:00 am). The vehicle used throughout
was 150 mM arginine-phosphate buffer, pH 7. When IGF-I and IGFBP-5 were administered
together, the IGF-I and IGFBP-5 was mixed together and allowed to incubate at room
temperature for 1 hour before administration so as to form an IGF-I+IGFBP-5 complex before
administration. Size separation of this IGF-I+IGFBP-5 complex showed that >80% of the IGF-I
eluted in the 50 kDa fractions, suggesting that the majority of the IGF-I exists as a complex in the
IGF-I+IGFBP-5 treatment solution. The mice were euthanised with ethrane and decapitated.
Blood and both femurs were collected and used for biochemical measurements of bone turnover.
The experimental procedures performed in this study are in compliance with the NIH guide for
the Care and Use of Laboratory Animals. All animals studies were reviewed and monitored by
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the Animal Studies Subcommittee at the Jerry L Pettis Veterans Administration Medical Center
(Loma Linda, California).
Experiment 1: Balb/c mice were divided into 3 groups of 8 animals each. Group 1 received
vehicle, group 2 received 13 pg/day of IGF-I and group 3 received 50 pg/day of IGFBP-5, all
groups received their treatment for 20 days. The 13 pg/20 g mouse dose of IGF-I (MW 7.7 kDa)
was determined based on previous studies of biological effects of IGF-I on body and cartilage
growth in mice (30). rhIGFBP-5 (MW 29 kDa) was administered in an equimolar dose (50 pg/20
g mouse) to that of IGF-I. The mice were tail bled on day 7 and 14. On day 21 the mice were
euthanised.
Experiment 2: C3H/HeJ mice were divided into 4 groups of 8 animals each. Group 1 received
vehicle, group 2 received 13 pg/day of IGF-I, group 3 received 50 pg/day of IGFBP-5 and group
4 received 13 pg/day of IGF-I + 50 pg/day of IGFBP-5, all groups received their treatment for 9
days. On day 10 the mice were euthanised.
Experiment 3: C3H/HeJ mice were divided into 2 groups of 6 animals each. These animals
received only one injection (day 1); group 1 received vehicle and group 2 received 50 pg/day of
IGFBP-5. On day 6 the mice were euthanised.
Experiment 4: C3H/HeJ mice were divided into 7 groups of 6 animals each. Groups 2-4 received
50 pg/mouse of IGFBP-5 and groups 5-7 received 13 pg/mouse of IGF-I. Group 1 was
euthanised at time zero as the baseline group; groups 2 and 5 were euthanised at 1 hour, groups 3
and 6 at 6 hours, and groups 4 and 7 at 24 hours post injection.
Serum collection: Whole blood was collected in 50 ml tubes, centrifuged at 3500 rpm in a cold
IEC Centra-7R centrifuge and serum was skimmed off and stored at -70°C until assayed.
Femur collection: Both femurs were dissected out of each carcass and cleaned of soft tissue,
being careful not to destroy the periosteum. Each bone was sectioned in the mid-diaphysis and
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rinsed in PBS at 4°C for 24 hours, followed by extraction in 0.01% Triton X-100 at 4°C for 72
hours. This bone extract was used for the ALP activity measurements.
Immunoblot: serum from animals in experiment 4 were subjected to electrophoresis on a 12%
acrylamide gel under denaturing conditions, transferred to a nitrocellulose membrane and the
membrane was immunoblotted for IGFBP-5 using the same antibody used in the IGFBP-5 RIA as
described previously (31).
Gel-filtration of treatment solution: To evaluate the extent of complex formation between IGF-I
and IGFBP-5, an aliquot of the IGF-I + IGFBP-5 treatment solution used for these in vivo studies
was subjected to size separation using Sephradex G75. The proteins were eluted with PBS
containing 0.1% BSA and 0.02% sodium azide, pH 7.2. The fractions were collected and assayed
for IGF-I after separation of IGF-I from the IGFBPs by a biospin protocol (see below). Molecular
weight standards were used to determine the elution position of the 40 kDa (IGF-I + IGFBP-5
complex) and 7.7 kDa (IGF-I) proteins.
3. Biochemical Assays
ALP Activity Assay: The ALP activity of the cell and bone extract was determined as previously
described (29).
Protein Assay: The protein concentrations were determined using the Lowry Folin assay (28).
IGF-I RIA: Serum IGF-I was measured by specific RIA after separation from the IGFBPs.
Because IGFBPs produce artifacts in IGF RIAs, it is essential to completely separate the IGFBPs
from the IGFs in order for the IGF-I determinations to be valid, as previously described (32). The
cross-reactivity of IGF-II in the IGF-I RIA is <0.5%. The sensitivity of the IGF-I RIA is <50
ng/L; the intra- and interassay coefficients of variation are less than 10% (33). This assay was
used to measure both endogenous mouse IGF-I and administered IGF-I.
IGFBP-5 RIA: Serum IGFBP-5 was measured by specific RIA using rhIGFBP-5 as standard and
tracer as previously described (34). None of the other high affinity IGFBPs cross-react with the
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antiserum used in this assay. The sensitivity of the IGFBP-5 RIA is <5 ng/ml; the infra- and
interassay coefficients of variation are less than 8%.
Osteocalcin Assay: Human osteocalcin levels in conditioned medium and serum were measured
by specific RIA (27). Mouse osteocalcin standard and tracer was purchased from BTI (Stoughton,
MA). The mouse osteocalcin RIA had <8% interassay variability. We have previously developed
and validated the mouse osteocalcin RIA (35).
ICTP Assay: Carboxytermmal cross-linked telopeptide of type I collagen was measured in the
mouse serum according to the manufacturers instructions using a Rat ICTP RIA Double Antibody
Kit purchased from DiaSorin (Stillwater, Minnesota). The sensitivity of this assay is 0.5 pg/L and
the mean recovery was 108.5%. The intra- and interassay coefficients of variation are less than
11% (36).
4. Statistics
Results are reported as mean ± SEM for 6 replicates for in vitro studies or 6-8 animals
per group for in vivo studies and compared by Student’s t test, ANOVA and Duncan post hoc test
as appropriate. Results were considered significantly different for P<0.05.
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D. Results
1. In Vitro Experiments
The effect of rhIGFBP-5 on osteoblast activity was evaluated by measurement of ALP
activity and osteocalcin production (37, 38). rhIGFBP-5 treatment increased osteocalcin levels in
the conditioned medium of MG63 and human osteoblast cells in a dose dependent manner with a
maximal increase (184±12% of control, P<0.01) at 100 ng/ml of rhIGFBP-5 in normal human
bone cells and (204±11% of control, PO.OOOl) at 300 ng/ml of rhIGFBP-5 in MG63 cells (Fig.
1). To evaluate that the rhIGFBP-5 induced increase in osteocalcin level was not due to increased
cell number, osteocalcin levels were standardized on the basis of cell protein to correct for
changes in cell number. rhIGFBP-5 (100 ng/ml) caused a significant increase in osteocalcin levels
even when the values were corrected for cellular protein (0.2 ± 0.02 ng osteocalcin per pg cell
protein in control versus 0.31± 0.06 ng osteocalcin per pg cell protein in rhIGFBP-5 treated cells,
P<0.01). Specific activity of ALP in cell extracts also showed a dose-dependent increase with and
without 10'8M 1,25 (OH)2 D3 (178±18% and 169±9% of control, respectively at 100 ng/ml
rhIGFBP-5, P<0.01) (Fig. 2). Similar results were obtained with normal human osteoblasts (data
not shown). 1,25 (OH)2 D3 has been shown to essential for the expression osteocalcin in human
osteoblasts and to increase ALP activity (39). Based on the previous findings that rhIGFBP-5
increased osteoblast cell proliferation (14, 20, 25) and the findings in this study that rhIGFBP-5
increased the differentiative functions of osteoblasts in vitro, we predicted that rhIGFBP-5 may
have a stimulatory effect on bone formation parameters in vivo. We therefore tested the effect of
rhIGFBP-5 on bone formation parameters in vivo using a mouse model.
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Figure 1: Effect of rhIGFBP-5 on osteocalcin production in MG63 and normal human osteoblasts.
Serum free cultures of MG63 or humans osteoblast were treated for 48 hours with different
concentrations of rhIGFBP-5 in the presence of 10'8 M 1,25 (OH)2 D3. Values are given in ng
osteocalcin per ml conditioned medium and are expressed as mean ± SEM (n=6 wells per group).
* = Duncan post hoc test with P<0.01.
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Figure 2: Effect of rhIGFBP-5 on ALP activity in MG63 cells. Serum free cultures of MG63 were
treated for 72 hours with different concentrations of rhIGFBP-5 in the presence or absence of 10'8
M 1,25 (OH)2 D3. ALP activity was then determined in the cell extract. Values are expressed as
percent of vehicle-treated control and are mean ± SEM (n=6 wells per group). * = Duncan post
hoc test with P<0.01. The specific activity of ALP in the control cultures in the absence and
presence of 10'8 M 1,25 (OH)2 D3 were 1.2+0.27 and 3.0+0.38 mU/mg protein, respectively.

133

2. In Vivo Experiments
To assess the effect of rhIGFBP-5 on bone formation and resorption parameters in vivo
we measured bone derived ALP activity and serum osteocalcin, as well as carboxyterminal crosslinked telopeptide of type 1 collagen (C-telopeptide).
Experiment 1: Daily subcutaneous administration of rhIGFBP-5 (50 ug/day) caused a significant
increase in serum osteocalcin levels as early as day 7 in Balb/c mice (Fig. 3); this increase was
maintained up to day 21. The magnitude of the rhIGFBP-5-induced increase in osteocalcin was
similar to that induced by an equimolar dose of IGF-I.
Experiment 2: To eliminate Balb/c strain-specific effects of rhIGFBP-5 on serum osteocalcin, we
evaluated IGFBP-5 effects in a different strain of mice. Consistent with the data in Balb/c mice,
9 days of rhIGFBP-5 treatment of C3H/HeJ mice significantly increased serum osteocalcin levels
(58%, p<0.001) (Fig. 4). As in the case of the Balb/c mice, in C3H/HeJ mice the rhIGFBP-5induced increase in serum osteocalcin was similar to that which resulted from administration of
an equimolar dose of IGF-I (65%, p<0.001) (Fig. 4) and the combination of IGF-I+rhIGFBP-5
(81%, p<0.001) (Fig. 4). rhIGFBP-5 treatment caused a significantly greater increase in ALP
activity in femoral bone extract compared to an equimolar dose of IGF-I or the combination of
IGF-I+rhIGFBP-5 (Fig. 5). To determine if rhIGFBP-5 modulates bone resorption as well as bone
formation parameters, we measured serum C-telopeptide levels. These were significantly reduced
by 20% and 29% of control (P<0.05) respectively in IGF-I and rhIGFBP-5 treated animals (Fig.
6).
Experiment 3: In order to determine if a single administration of rhIGFBP-5 would cause an
increase in serum osteocalcin and bone ALP activity, we administered a single injection of
rhIGFBP-5 on day 1, and on day 6 collected the serum and performed biochemical measurements
of bone formation parameters. The time frame for this experiment is based on studies where
systemic IGF-I administration was evaluated of several days to determine the optimal time to
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Figure 3: Effect of rhIGFBP-5 or IGF-I on serum levels of osteocalcin in mice. Balb/c mice were
treated with rhIGFBP-5 (50ug/day) or IGF-I (13ug/day) or vehicle for 20 days. Animals were tail
bled on days 7 and 14 to obtain blood in which to measure the serum osteocalcin levels. Values
are expressed as percent of vehicle-treated control and are mean ± SEM (n=6 mice per group). *
= Duncan post hoc test with P<0.05. The vehicle-treated control is 437 ng osteocalcin/ml serum
on day 7, 358 ng/ml on day 14 and 209 ng/ml on day 21.
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Figure 4: Effect of rhIGFBP-5 on serum levels of osteocalcin in C3H/HeJ mice. Equimolar doses
of rhIGFBP-5 (50ug/day) and/or IGF-I (13ug/day) were given daily for 9 days prior to the serum
osteocalcin determination. Values are expressed as ng of osteocalcin per ml of serum ± SEM (n=6
mice per group). * = Duncan post hoc test with
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Figure 5: Effect of rhIGFBP-5 on bone ALP in C3H/HeJ mice. Equimolar doses of rhIGFBP-5
(50ug/day) and/or IGF-I (13ug/day) were given daily for 9 days prior to the determination of
bone ALP activity. Values are expressed as mU of ALP activity per mg of total protein in the
bone extract ± SEM (n=6 mice per group). * = Duncan post hoc test with P<0.001.
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Figure 6: Effect of rhIGFBP-5 on carboxyterminal cross-linked telopeptide (C-telo) of type I
collagen in C3H/HeJ mice. Equimolar doses of rhIGFBP-5 (50ug/day) and/or IGF-I (13ug/day)
were given daily for 9 days prior to the determination of bone ALP activity. Values are expressed
as ng of C-telo per ml of serum ± SEM (n=6 mice per group). * = Duncan post hoc test with
P<0.05.
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evaluate the changes in serum levels of bone formation markers (data unpublished). In this
experiment, both serum osteocalcin (124% of control, P<0.001) and bone ALP (184% of control,
P<0.001) were increased at the lowest dose tested (Fig. 7).
Experiment 4: To evaluate if rhIGFBP-5 increases bone formation parameters by a mechanism
involving an increase in circulating levels of IGF-I we measured serum IGF-I levels in mice
following administration of rhIGFBP-5. As a control, we administered an equimolar dose of
IGF-I. Serum IGF-I levels were not significantly increased at either 1, 6 or 24 hours (Fig. 8)
following rhIGFBP-5 injection, however in the control IGF-I treated animals, serum IGF-I levels
were increased by 111% of baseline (P<0.01) at 1 hour indicating that the administered IGF-I had
reached the circulation. In addition, serum IGFBP-5 levels were increased from 103 ± 24 ng/ml
(at baseline) to 353 ± 52 ng/ml 1 hour after IGFBP-5 administration and had returned to baseline
value at 24 hours (102 ± 40 ng/ml). In order to determine if the administered IGFBP-5 remains in
an intact form, pooled sera from baseline and IGFBP-5 treated groups (1 hour after treatment)
were subjected to immunoblot analysis. Figure 9 shows that serum levels of both intact and
fragment forms of IGFBP-5 were increased 1 hour after IGFBP-5 administration.
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Figure 8: Serum levels of total IGF-I in the IGF-I and IGFBP-5 treated animals. After a single
administration of IGF-I or IGFBP-5, animals were sacrificed at 1, 6 and 24 hours post-injection,
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mean value for the baseline control is 209 ± 17 ng IGF-I/ml serum.
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E. Discussion
In the present study, we describe for the first time that in vivo systemic administration of
rhIGFBP-5 alone or in combination with IGF-I stimulates bone formation parameters in mice
over the short term. Our data also demonstrate that rhIGFBP-5 treatment alone increased the
activity of osteoblast-line cells in serum-free culture in vitro (increased ALP activity and
osteocalcin production). This, together with previously published data showing that rhIGFBP-5
also increases osteoblast cell proliferation (14, 40) provides evidence that IGFBP-5 has a unique
role among the IGFBPs in promoting osteoblast cell proliferation and activity, and consequently
bone formation.
Osteoblasts have been shown to produce all six of the high affinity IGFBPs known to
date (4, 12, 16), although the amount of each IGFBP varies from cell line to cell line (41). There
have been a number of in vitro studies which examined the effects of various IGFBPs on
modulating the biological effects of IGF on various cell types including osteoblasts (4, 12, 13,
16), however, there have been very few studies on the in vivo effects of IGFBPs, but those that
are published are limited to IGFBP-3. In this regard, Bagi et al. (42-44) have shown that
systemic administration of IGFBP-3 in combination with IGF-I increased bone formation in
ovariectomized rats in a dose-dependent manner with optimal effects at 7.5 mg/kg of IGF-I
complexed to an equimolar dose of IGFBP-3.
In these studies, the complex of IGFBP-3+IGF-I produced consistently greater effects
than IGF-I alone in stimulating bone formation. According to the authors, this complex has a
much longer half-life in the circulation and lowers blood glucose levels to a lesser extent than
IGF-I alone because the IGF-I+IGFBP-3 binary complex binds to the circulating free acid labile
subunit (ATS) in the blood to form a 150 kDa complex which does not cross the vascular
endothelium.
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Figure 9: Western immunoblot analysis of pooled mouse sera before and 1 hour after treatment
with IGFBP-5. Serum proteins were separated by SDS-PAGE, transferred to a nitrocellulose
membrane and immunoblotted with IGFBP-5 antiserum. The molecular markers in kilodaltons
are shown on the left. Both intact (29 kDa) and fragment (21 kDa) forms of IGFBP-5 were
increased after IGFBP-5 treatment.
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Surprisingly, in our study the combination of IGF-I+IGFBP-5 was less effective that
IGFBP-5 alone in modulating changes in biochemical measurements of bone turnover in some,
but not in other experiments. The reason for this discrepancy is not clear at this time. One
potential explanation is that, similar to IGFBP-3, IGFBP-5 when complexed to IGF-I has been
shown to bind ALS (45). It is therefore possible that upon administration of IGF-I+IGFBP-5,
some of this complex may exist in the 150 kDa complex by binding the ALS. This large
molecular weight complex may trap the administered IGF-I, as well as the IGFBP-5 in the serum,
since the 150 kDa complex is too large to cross the vascular endothelium. Further studies are
needed to test this possibility.
In contrast to the IGF-I+IGFBP-3 studies, our study shows that systemic administration
of rhIGFBP-5 alone increased bone formation parameters in mice. IGFBP-5 treatment at the dose
used in this experiment (50 jig/mouse) did not significantly alter the circulating levels of total
IGF-I, or the relative ratio of serum IGF-I in the 150 and 50 kDa (data not shown). Because
IGFBP-5 has been shown to bind to ALS only when complexed to IGF-I and because only a
small amount (<1%) of total IGF-I is present in the free form, it is possible that the majority of
IGFBP-5 administered remains in a free form and is thus freely available to target tissues. We and
others have reported indirect evidence showing that IGFBP-5 may affect osteoblasts by an IGFindependent mechanism (14, 40), raising the possibility that the bone-forming effects of IGFBP-5
may, in part, be mediated by an IGF-independent mechanism.
Although, IGFBP-5 administration did not modulate circulating levels of IGF-I, we did
not determine the effects of administered IGFBP-5 on local production of IGF-I or other IGF
system components, which could provide a mechanism for the bone-forming effects of IGFBP-5.
In addition, IGFBP-5 has been shown to bind to hydroxyapatite and extracellular matrix proteins
and thereby may be involved in fixing locally produced IGFs in bone, and therefore it is possible
that IGFBP-5 treatment may increase IGF-I content in bone and bring about the increases in bone
formation parameters seen in this study. IGFBP-3 has also been shown to bind to certain
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extracellular matrix proteins, but not to hydroxyapatite (18, 46). Because IGFBP-3 content in
bone is much less than that of IGFBP-5 (18), this mechanism of action may not be as important in
mediating IGFBP-3 effects to increase bone formation in the presence of IGF-I. Further studies
are needed to establish that the mechanism by which IGFBP-5 mediates its bone forming effects
in vivo is different to that of IGFBP-3.
Our present study does not identify the target cells involved in mediating the bone
forming effects of IGFBP-5 since we indirectly evaluated bone formation by biochemical
measurements of osteoblast cell activity and osteoblast cell products and not by direct
histomorphometric methods. In this regard, the findings that serum osteocalcin and ALP activity
in bone were increased by day 5 following a single injection of IGFBP-5 suggest that IGFBP-5
may affect existing osteoblastic cells. Further long term studies using histomorphometric
techniques are needed to evaluate the target cells of IGFBP-5 since biochemical markers in serum
and bone extracts are only indirect measurements of osteoblast cell number and activity.
In contrast to the effects on bone formation parameters, short-term administration of both
IGFBP-5 and IGF-I decreased serum C-telopeptide levels, a marker of bone resorption. In
contrast to these effects in mice, short-term administration of IGF-I has been shown to increase
bone resorption markers in elderly postmenopausal women (47). There are a number of potential
explanations for the observed differences between IGF-I effects in mice and humans. IGF-I may
have different effects in mice than in humans, Jonsson et al. (48) showed that IGF-I had no effect
on 45Ca release from prelabeled neonatal mouse calvarial bones, although IGF-I pretreatment
increased formation of multinucleate tartrate resistant acid phosphate positive cells in murine
bone marrow cultures. In addition, IGF-I treatment also inhibited bone resorption-induced by
PGE2 and l,25(OFI)2D3 (48). Alternatively, the IGF-I effects on bone resorption may be different
depending on estrogen status. The mice used in these studies were intact young animals (7
weeks) as opposed to the human IGF-I studies that were done in postmenopausal women. Further
studies are needed to evaluate if IGF-I also decreases bone resorption in estrogen deficient
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(ovariectomized) older mice and if so what is the molecular basis for the observed differences in
IGF-I effects on bone resorption between mice and humans.
In conclusion, this study demonstrates for the first time that a single administration of
IGFBP-5 increases bone formation, however this increase in bone formation parameters is not
mediated by increases in serum IGF-I levels. We also show that IGFBP-5 administration
decreases bone resorption parameters in mice. We have also shown that IGFBP-5 is as potent as
IGF-I in stimulating bone formation parameters. Long term studies on the effects of IGFBP-5 on
bone histomorphometry, bone density and bone strength are essential to confirm the anabolic
effects of IGFBP-5 on bone.
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CHAPTER FIVE

GENERAL DISCUSSION AND CONCLUSIONS
A. General Discussion
Osteoporosis is characterized by decreased bone mass and decreased trabecular
continuity, thickness and number leading to a fragile skeleton that is predisposed to fracture with
minimal trauma. Areal bone density is a good indicator of the risk of fracture, and bone density
at any one time, is the sum of the peak bone density attained, less the bone lost since this peak
bone density was attained. Therefore the risk of an individual to develop osteoporosis depends
on: 1) the amount of peak bone density attained during adolescence and 2) the rate of bone loss
that occurs at menopause and thereafter.
Peak bone mass is attained during the third decade of life, soon after the end of puberty
and sexual maturity. Forty to fifty percent of this peak bone mass is gained during pubertal
growth, therefore the bone mass accretion during this period of growth is critical for the
development of adequate peak bone density. The higher the peak bone density attained, the less
susceptible an individual will be to developing osteoporosis later on in life. Several factors
modulate the peak bone mass that an individual attains, including diet (especially protein and
calcium content), level of activity (exercise), exposure to sunlight (vitamin D), timing of puberty,
and genetic heritability (1). Of these factors, the genetic component has been shown to contribute
70-80% of the variability in peak bone density (1-5). Therefore the identification of the genes
responsible for modulating the attainment of peak bone density is essential in an effort to
understand the mechanisms involved and the critical period for studies on genes involved in the
development of peak bone mass.
The first study presented in this dissertation (see Chapter Three) identifies the timing of
rapid gains in bone density and the relative contribution of these gains in bone density to the very
different peak bone density in two inbred strains of mice. Characterization of the gene expression
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during these periods of rapid gain in bone density will elucidate the mechanisms responsible for
the increase in bone mass and density. Knowing when the most rapid gain in bone density occurs
will aid in the design of future studies examining the potential use of therapeutic agents that
stimulate bone formation and therefore increase peak bone mass.
An individual with high peak bone density could develop osteoporosis if the subsequent
bone loss rate is high. The rate of bone loss is different from person to person, some people loose
bone faster than others and for 8-10 years following menopause bone loss is accelerated in
women. Therefore the rate of bone loss will determine if and when an individual will develop
osteopenia and therefore be at risk to fracture. If the first symptom of osteoporosis is the
incidence of a fracture, that individual already has low bone mass and associated high fracture
risk. The ideal treatment for such an individual would be to increase bone mass and reduce the
fracture risk associated with low bone mass. However, the therapeutic agents approved for use in
the treatment of osteoporosis only inhibit bone resorption thus preventing further bone loss, and
have limited ability to increase bone mass.
Antiresorptive agents approved for use in osteoporosis are hormone replacement therapy
(HRT), selective estrogen-receptor modulators (SERM), calcitonin and bisphosphonates. No
drugs that stimulate bone formation have been approved for routine clinical use. Clinical trials
are on going using potential systemic and local anabolic agents such as PTH, fluoride, and other
growth factors. PTH has shown great promise in its ability to increase bone formation in both
animal models and in humans when administered in a discontinuous manner (6-10). Fluoride
treatment has also been shown to increase osteoblast proliferation in vitro and to increase
osteoblast number and fluoride deposition in mineralized bone matrix in vivo (11). These
changes lead to increased bone mass but not necessarily decrease fracture risk. Other potential
but not yet approved systemic therapies for use in the treatment of osteoporosis are GH and IGFI, both of which have been successfully shown to increase bone density in children and adults
with GH deficiency and Laron dwarfs, respectively (12-20). In these studies GH/IGF treatment
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was more successful in children whose skeleton appears to be more responsive to these therapies
than are adult skeletons.
The second study presented in this dissertation (see Chapter Four) describes the effect of
a novel growth factor, IGFBP-5, when administered either locally or systemically to increase
bone formation parameters in mice. If this anabolic effect of IGFBP-5 can be demonstrated in
humans, it holds great promise as a future therapy to increase bone mass in osteopenic patients.
The findings of the puberty and IGFBP-5 in vivo studies and the implications of these
findings for future osteoporosis treatment and prevention are discussed in more detail below.
1. Bone Accumulation Leading to Peak Bone Density
The study presented in Chapter Three of this dissertation found that the most rapid
accumulation of bone mineral content and volumetric bone density occurred during postnatal and
pubertal growth. This is the first such report of the timing of bone accretion during the different
periods of growth in mice. The characterization of the timing of rapid bone growth and mineral
accretion is important not only for the study of growth, but also, for the identification of the
optimal period for enhancing bone mass and mineralization in an effort to attain a higher peak
bone mass.
Comparison of a high bone density strain C3H/HeJ (C3H) to a low bone density strain
C57BL/6J (B6) of mice showed that the dramatic increase in bone mineral content and volumetric
density occurred during postnatal and pubertal growth in both strains. C3H mice gained more
bone faster than did B6 mice during these periods leading to the dimorphism in bone density,
mineral content and cortical thickness between these two strains. These mice represent the
naturally occurring variation in bone density observed in the human population, so that
identification of the differences that lead to the dimorphism in bone mass between these two
strains of mice will aid development of preventive therapies to increase bone mass in low density
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human subjects. Increasing bone mass which will protect such individuals from developing
osteopenias' later in life.
Identical and nonidentical human twin studies have helped to identify the large genetic
component that contributes to the determination of peak bone mass. In studies measuring bone
mass, there was a larger intrapair difference observed in nonidentical twins than in identical twin
sets, consistent with the identical genetic makeup of identical twins versus only half of the
genome being identical in nonidentical twins (21). Pocock et al. assessed lumber spine and
femoral neck bone density, and found that up to 80% of the variability in bone density at these
sites was genetically determined, especially in the lumber spine where the bone is almost
exclusively trabecular (22). A confounding factor in the interpretation of these twin studies is
that not only do twins share a similar genome but they also are more likely to share a similar life
style. Life style factors that play a role in bone mass determination include diet, exercise, habits
(smoking and drinking) and geographic location. These additional factors may allow for over
estimation of the genetic contribution to bone density observed in identical twins (23). To define
the contribution of the genome to bone density, inbred animal models, such as mice, allow
environmental confounding factors to be controlled when comparing the observed differences
between various inbred strains of mice. Environmental factors such as housing, diet and
dark/light cycles can be kept constant for all animals in each study. Inbred animals are essentially
identical twins, with identical genomes and so allow the effect of different genetic combinations
to be studied without confounding the genetic contribution with environmental contributions.
Our study comparing two such inbred strains of mice allowed us to determine that the genetic
makeup of C3H mice is such that they gain more bone mineral content, bone density and cortical
thickness before and during puberty than do B6 mice, therefore C3H mice attain a higher areal
peak bone density than do B6 mice.
From our study, it is apparent that the postnatal and pubertal growth periods are critical
periods in the development of bone mass and density in both strains of mice. The identification
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of gene expression unique to each of these growth periods will be important in determining which
genes may be responsible for the rapid growth and the increase in bone mass and density. Also,
the comparison and identification of the differences in gene expression between these two strains
of mice during these two growth periods will help to determine which genes are responsible for
developing the bone mass and density dimorphism between the two strains. Candidate genes can
be identified using several techniques: 1) the traditional mRNA isolated from bone, followed by
northern blotting for known gene/s expressed during the growth periods under study; 2)
microarray analysis of mRNA from bones harvested during postnatal or pubertal growth periods
and hybridized to known gene arrays; and 3) protein from conditioned medium collected from
osteoblasts derived from bones collected during the different growth periods can be characterized
by the molecular weight of individual proteins and the relative concentration of those proteins
using the newly developed proteomics technology (Surface-Enhanced Laser Desorption and
Ionization). Differences in protein profiles will help to identify the candidate protein/s associated
with the differences in bone mass between the two strains of mice. These methods will help to
identify the differential gene expression that characterizes each growth period and differences in
gene expression between the two inbred strains of mice during these periods, allowing the genes
responsible for the differential development of bone mass, volume and density to be identified
and further characterized.
From previous studies comparing adult C3H and B6 mice (24-27), we know that the
difference in bone mass, volume and density is not limited to any one skeletal site, therefore the
potential gene product/s responsible for the differences between the two strains could be systemic
in distribution and effect. Although the regulation of locally produced factors by osteoblasts that
act in an autocrine/paracrine manner could be responsible for the differences in bone density,
mass and mineral content between the two strains.
Based on studies using null mice generated by spontaneous or targeted homologous
recombinant technology, we know that GH and its down stream effector, IGF-I, are potent
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regulators of bone growth. Various types of GH deficient mice have been described (28-32) and
all exhibit retarded overall growth, including skeletal growth but these mice reach sexual maturity
and are fertile. A similar dwarf phenotype is seen in IGF-I KO mice (33-35) which also have
retarded overall growth, including skeletal growth, but these KO mice do not reach sexual
maturity and therefore are infertile. A case study report of a young man with a disrupted IGF-I
gene also had impaired overall growth, including a bone density that was five standard deviations
below normal control values (36, 37). These studies emphasize the important role of the GH/IGF
axis in normal growth and development, as well as skeletal growth and mineralization. In our
study, serum IGF-I levels were higher in the higher bone density C3H compared to the B6 mice.
We also found that serum IGF-I levels correlated significantly with bone densitometric,
geometric and physical parameters during postnatal growth, when the differences between the
strains is being set up. Similarly Rosen et al. reported that serum IGF-I levels were 35% higher
in C3H mice compared to B6 mice; F2 intercrosses of these two strains with the highest bone
density also had the highest serum IGF-I levels, and visa versa. These data suggest that the
GH/IGF axis maybe a potential candidate system for determining differences in not only body
growth, but also in bone growth and density. However, peak bone density is regulated by
multiple genes that map to many quantitative trait loci (5, 38-40) so that the GH/IGF axis genes
are only some of the players in this regulation.
In conclusion, the timing of the rapid increase in bone mineral content and density in
mice occurs during postnatal and pubertal growth. C3H mice gain more bone, faster than B6
mice during these growth periods and male mice gain more bone than female mice during puberty
so that males have greater bone size, density and mineral content than do female mice. Therefore
postnatal and pubertal growth periods maybe the best time to implement interventive therapies
aimed at manipulating bone accretion.
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2. IGFBP-5: A Novel Bone Anabolic Factor
The study presented in Chapter Four of this dissertation, found that administration of
IGFBP-5, independent of circulating IGF-I, increased both local and systemic bone formation
parameters and decreased systemic bone resorption parameters in mice. Histomorphometric
analysis of bones following long term treatment with IGFBP-5 is needed to demonstrate this
increase in bone formation and the cells involved in the process.
Bone formation is dependent upon osteoblast cell number and activity. IGF-I and -II
have been shown to modulate both of these processes. IGFBPs on the other hand, either enhance
or inhibit these IGF actions. Of the six high affinity binding proteins, IGFBP-5 has consistently
been shown to enhance the mitogenic activity of IGFs on osteoblasts in vitro (41-44). IGFBP-5
has greater binding affinity for IGF than does the IGF type 1 receptor, but when bound to
extracellular matrix proteins this binding affinity is decreased allowing IGFs to shift to the
receptor and stimulate cell proliferation. (45-47). These characteristics of IGFBP-5 support the
hypothesis that IGFBP-5 acts in an IGF-dependent manner to increase cell proliferation.
Osteoblasts have also been shown to express an IGFBP-5 receptor (42, 48, 49). Previous studies
have shown that IGFBP-5 on its own, without any added or endogenous IGFs can increase cell
proliferation (42, 43, 48). Therefore IGFBP-5 may act in both an IGF-dependent and IGFindependent mechanism to increase bone formation.
In our study, IGFBP-5 treatment increased bone formation parameters in as little as 5
days. Therefore IGFBP-5 is most likely acting on differentiated osteoblasts to increase matrix
production and therefore increase bone formation parameters rapidly. Since osteoblast
recruitment from preosteoblasts takes several days, is unlikely that the increase in bone formation
seen at 5 days is caused by IGFBP-5 effects on preosteoblasts. However, long term treatment
with IGFBP-5 will determine if IGFBP-5 has the ability to recruit new osteoblasts from the
osteoprogenitor pool and therefore increase the number of active osteoblasts in the long term.
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Bone resorption is due to osteoclast formation and activation. IGFBP-5 is unlikely to
modulate osteoclast activity directly but it may play a role in the regulation of osteoclastogenesis
by its action on osteoblasts. Such a possibility is supported by recent studies that have shown that
osteoblasts modulate the effects of other systemic hormones such as PTH, PGE2 and 1,25 vitamin
D3, by producing osteoclast differentiation factor (ODF) which stimulates osteoclast formation
and activation by binding the membrane bound receptor activator of NF-kappaB (RANK) (50) on
the osteoclast membrane (51). Or in response to TGFp, osteoblasts produce osteoprotegrin
(OPG) (51) that is a soluble decoy receptor that binds ODF and inhibits its actions (52). In this
study, IGFBP-5 decreased bone resorption parameters and the mechanism responsible for this
effect remains to be determined.
Several studies using other IGFBPs in vitro and in vivo are present in the literature. Bagi
et al. used IGFBP-3 with rhIGF-I (53-57) in an ovariectomized rat model to elucidate the in vivo
role of IGF-I+IGFBP-3 on bone formation. IGF-I treatment both in vitro and in vivo has been
shown to increase osteoblast proliferation and bone formation (58-60) and therefore raised the
possibility that IGF-I may be a possible treatment for osteopenias such as osteoporosis. However,
the hypoglycemic side effects of pharmacological doses of IGF-I (insulin-like activity) precludes
it use alone. Previous in vitro studies have shown that IGFBP-3 can either inhibit or enhance the
mitogenic actions of IGF-I depending on the stage of growth and differentiation of the cells used
in the assays (61, 62). Coadministration of IGFBP-3 has been shown to block the hypoglycemic
activity of IGF-I (63) and increase the circulating half-life of IGF-I in the serum (63). Bagi et al.
treated ovariectomized rats for 8 weeks with doses of either IGF-I alone (0.9 and 2.6 mg/kg) or
IGF-I (0.9, 2.6 and 7.5 mg/kg) complexed to an equimolar concentration of IGFBP-3 starting 8
weeks after ovariectomy. They found that treatment with either formulation increased body
weight due to increased lean body mass compared to controls; and that a dramatic increase in
periosteal, modeling-dependent formation, coupled with decreased or unchanged resorption in
endocortical bone formation resulted in a dose dependent increase in cortical thickness and cross-
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sectional area in IGF-I+IGFBP-3 complex treated animals (56). As well as, an increased bone
mineral content and density due to increased bone deposition at both endocortical and periosteal
surfaces of the femoral cortex (55). The bones of the IGF-I+IGFBP-3 complex treated animals
had higher torque to failure compared to control animals. Thus from these studies Bagi et al.
suggest that IGF-I+IGFBP-3 treatment in osteopenic humans may help to promote bone
formation and restore cortical thickness, strength and quality.
In contrast to Bagi et als ’ studies, we treated our mice with IGF-I alone, an equimolar
dose of IGF-I+IGFBP-5 complex, or an equimolar dose of IGFBP-5 alone. Because IGFBP-5
has been shown to consistently enhance the mitogenic activity of IGFs in vitro; to enhance cell
proliferation via its own receptor, which is expressed on osteoblasts (42, 48, 49); and to avidly
bind to hydroxyapatite (64) and therefore to be stored in bone matrix along with its bound IGFs;
we anticipated that IGFBP-5 would be anabolic to bone in vivo. In our study, we found that
administration of both IGF-I+IGFBP-5 complex and IGFBP-5 alone increased bone formation
parameters in a more potent manner than did IGF-I alone. However, the IGF-I+IGFBP-5
complex was not more potent than IGFBP-5 alone. Although IGFBP-3 and IGFBP-5 are similar
in some respects: 1) they both bind to extracellular matrix proteins (65), and 2) when bound to
IGFs, they also bind to the acid labile subunit (ALS) to form a 150-kDa complex in the
circulation (66-69); IGFBP-3 and IGFBP-5 have several distinct differences: 1) IGFBP-3 has
been shown to inhibit or enhance IGF-I actions depending on the model, dose and culture
conditions used (61, 62), whereas IGFBP-5 consistently enhances IGF actions in osteoblasts; 2)
IGFBP-3 does not bind hydroxyapatite like IGFBP-5 does (70-72); therefore 3) IGFBP-3 is
stored in much smaller quantities in bone than is IGFBP-5; and in serum, IGFBP-3 preferentially
exists in a 150-kDa complex and little IGFBP-3 is found in the 50-kDa IGF pool, while IGFBP-5
bound to IGF can exist in the serum in either of these two forms (66). The 150-kDa complex is
too large to cross the vascular endothelium and leave the circulation thereby trapping the bound
IGFs in the serum, while the smaller 50-kDa complex readily crosses the vascular endothelium to
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reach the tissues. Therefore IGF-I+IGFBP-3 complex treatment increases the half-life of IGF-I in
the circulation while administered IGFBP-5 rapidly leaves the circulation and once in the
extracellular space can act on its own receptor to stimulate bone formation. Therefore we believe
that IGFBP-5, due to its unique characteristics may be a more suitable therapeutic than IGFI+IGFBP-3 because it specifically targets itself to bone and thus will have less tissue non-specific
side effects.
We also demonstrate that IGFBP-5 increases bone formation parameters independent of
changes in circulating IGF-I levels. This may be due to the actions of the excess administered
IGFBP-5 that is free in the circulation because there is little free IGF available for it to bind to.
This free IGFBP-5 readily leaves the circulation to act at the tissue level. At the cellular level,
IGFBP-5 may also act in an IGF-independent manner by binding to its own receptor. In vitro
studies using MG63 cells that produce little IGFs, show increased cell proliferation when treated
with IGFBP-5 (44). And IGFBP-5 analogs that have decreased IGF binding affinity also increase
cell proliferation (73). These in vitro findings demonstrate that IGFBP-5 may very well increase
bone formation in an IGF-independent manner in vivo.
It is known that serum contains and osteoblasts produce protease/s capable of degrading
IGFBP-5. To determine if the rhIGFBP-5 we administered remains intact, or if it is rapidly
degraded after administration, we subjected pooled sera from baseline and rhIGFBP-5 treated
animals one hour after treatment to SDS-PAGE followed by western blotting using an antiIGFBP-5 antibody (the same as that used in the IGFBP-5 RIA). The results showed that both the
intact and fragment forms of IGFBP-5 were increased in rhIGFBP-5 treated animals following
treatment. Several in vitro studies (42, 73) have shown that degradation fragments of IGFBP-5
have less potent mitogenic effects than does intact IGFBP-5. Therefore, although some of the
administered IGFBP-5 is not intact, these fragments may still contribute to the increase in bone
formation parameters observed.
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In contrast to the stimulatory effects of IGFBP-5 on osteoblasts in vitro, IGFBP-4 has
been consistently shown to inhibit IGF action. We would therefore anticipate IGFBP-4 and -5 to
exhibit different effects in vivo. In this regard, Miyakoshi et al. recently reported on the effect of
local and systemic administration of IGFBP-4 in vivo using a mouse model system (74). They
found that similar to the inhibitory effect of IGFBP-4 on IGF actions in vitro (42, 75), local
administration of IGFBP-4 had an inhibitory effect on IGF-induced bone formation, but when
administered systemically IGFBP-4 increased bone formation parameters in serum and bone
extract. This dimorphic effect maybe explained by the fact that local increases in IGFBP-4
sequester IGFs from their receptors and therefore inhibit their action; while systemic increases in
IGFBP-4 were shown to increase the bioavailable (50-kDa) IGF pool in serum and thus allow
more IGF to reach the tissue. Once in the tissue IGFBP-5 can be released by proteolysis of
IGFBP-4 to act on its target cells. Osteoblasts produce an IGF-dependent IGFBP-4 specific
protease (76) that could increase the dissociation of IGF from the degraded IGFBP-4 fragments
and enhance the action of IGF on bone formation. In our study using IGFBP-5, systemic
administration of IGFBP-5 did not change the distribution of IGF in the 50 and 150-kDa pools,
therefore IGFBP-5’s effect on bone formation parameters is mediated by a different mechanism
to that of IGFBP-4 and appears to be independent of changes in the distribution of systemic IGFI. This difference could also be due to the much higher doses of IGFBP-4 compared to IGFBP-5
used in the two different systemic studies.
In summary, we postulate that the increased concentration of systemically administered
IGFBP-5 increases bone formation parameters through its own receptor found on osteoblasts, and
that it decreases bone resorption parameters by an as yet unidentified mechanism/s. This
increased bone formation and decreased bone resorption may lead to a net gain in bone mass.
Therefore, IGFBP-5 appears to have great potential as an anabolic agent to increase bone mass in
vivo. Future studies to characterize the target cells and the long-term effect of IGFBP-5 treatment
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on bone strength and density in vivo are the obvious next steps in determining IGFBP-5s’ clinical
potential.
B. Conclusions
Both of the studies presented in this dissertation significantly contribute to the in vivo
literature related to the manipulation of bone formation and its relationship to osteopenia,
especially osteopenia associated with osteoporosis. The identification of the timing of rapid bone
accretion during postnatal and pubertal growth will allow use of inbred mouse models for
development of preventive enhancement of bone accretion during these periods that will protect
individuals with predisposing genetics from developing osteoporosis later in life. Identification
of candidate genes responsible for the differences in the bone accretion rate in the high density
C3H mice compared to the low density B6 mice will elucidate optimal time frames and identify
growth factors that will modulate bone accretion during these rapid growth phases. Such
intervention ideally will increase the peak bone density attained in an individual with genetics
that dictate a low peak bone density and therefore would be predisposed to developing
osteoporosis later in life. The IGFBP-5 study demonstrated for the first time that IGFBP-5 given
systemically increased bone formation and decreased bone resorption parameters in mice. Future
studies will determine if this is therefore possible in humans. Therefore a possible next step
might be to administer IGFBP-5 during the rapid postnatal and pubertal growth periods in mice
and determine if this treatment will significantly increase the final peak bone mass of the model
system used.
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